Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Gynecologic Oncology›Condition·Updated Jun 24, 2026·v1

Cervical Cancer v2

Cervical cancer is a paradigm of viral carcinogenesis — almost entirely HPV-driven, vaccine-preventable through HPV vaccination (most effective before age 17), and screen-curable at the CIN stage through cytology, primary HPV testing, and precursor treatment, yet it persists as the fourth most common cancer in women globally because vaccination and organized screening reach fewer than one in three women in the highest-burden regions of sub-Saharan Africa, Latin America, and South Asia. The 2018 FIGO staging revision incorporated MRI, PET-CT, and pathology into clinical staging and split stage IIIC by nodal level and detection method, anchoring every subsequent management decision. Treatment hinges on stage: simple hysterectomy for IA1 without LVSI, simple hysterectomy with nodal assessment for IA1-LVSI through IB1 ≤2 cm per SHAPE, open radical hysterectomy for IB1 >2 cm and IIA1 (minimally invasive radical hysterectomy contraindicated per LACC), cisplatin-based chemoradiation with MR-guided adaptive brachytherapy for IB2-IVA (EMBRACE-I local control >92% in IIB), and pembrolizumab plus platinum chemotherapy ± bevacizumab for IVB or recurrent disease per KEYNOTE-826. Histology matters: squamous cell carcinoma is immune-"hot" and PD-L1 responsive; gastric-type adenocarcinoma is HPV-independent, immune-"cold," and markedly worse; small cell/neuroendocrine carcinoma follows distinct platinum-etoposide ± immunotherapy pathways. Molecular biomarkers now refine management — PIK3CA mutation (~25–30%) and PD-L1 CPS for actionability, ctHPV DNA for molecular residual disease and relapse prediction, and p16/Ki-67 dual-stain for HPV-positive triage. Prevention and equity — the WHO 90-70-90 target — remain the highest-yield interventions in oncology, with the 6-fold global mortality disparity between developed and developing regions reflecting not biology but access to vaccination, screening, and treatment.

High Evidence418 references·1,688 words·7 min read·v1
cervical cancergynecologic oncologyHPVhuman papillomaviruscervical intraepithelial neoplasiaCINFIGO 2018 stagingcervical screeningprimary HPV testingHPV vaccinationcolposcopysentinel lymph node biopsyradical hysterectomytrachelectomychemoradiationcisplatinMRI-guided adaptive brachytherapypembrolizumabbevacizumabtisotumab vedotinKEYNOTE-826KEYNOTE-A18LACC trialSHAPE trialEMBRACE-IctHPV DNAPIK3CAPD-L1p16AIDS-defining malignancycervical adenocarcinomasmall cell cervical cancergastric-type adenocarcinomafertility preservationcervical cancer in pregnancyWHO 90-70-90

Quick Reference

RxDrug of choiceCisplatin 40 mg/m² IV weekly × 5–6 cycles concurrent with external-beam radiotherapy for locally advanced disease (IB2–IVA); pembrolizumab 200 mg IV every 3 weeks + platinum chemotherapy ± bevacizumab 15 mg/kg for stage IVB or recurrent disease (KEYNOTE-826).
AltAlternativesCarboplatin AUC 5–6 weekly when cisplatin contraindicated by renal dysfunction or ototoxicity; cemiplimab 350 mg IV every 3 weeks for PD-L1 CPS≥1 disease after platinum failure (EMPOWER-Cervical 1); tisotumab vedotin for pretreated recurrent/metastatic SCC; paclitaxel, topotecan, or vinorelbine ± bevacizumab for platinum-resistant recurrence.
⊘AvoidMinimally invasive radical hysterectomy outside prospective protocols (LACC trial: DFS HR 1.65 vs open) [300]; non-protocol omission of brachytherapy in locally advanced disease; vaginal delivery with active invasive cervical cancer; cisplatin in first trimester of pregnancy; concurrent durvalumab + CRT (CALLA negative) — pembrolizumab preferred (KEYNOTE-A18 positive) [297]; hormone replacement therapy in untreated or uninvestigated abnormal vaginal bleeding.
DxTest of choicePelvic MRI with DWI for local tumor assessment (ACRIN 6651/GOG-183 reference standard) [229]; FDG-PET/CT for nodal and distant staging; colposcopy with directed biopsy (± endocervical curettage) for tissue diagnosis; p16 IHC for HPV-driven confirmation; PD-L1 CPS for immune checkpoint inhibitor eligibility; SLN biopsy with ultrastaging (cytokeratin AE1/AE3) for surgical nodal staging in early disease.
ScKey scoreFIGO 2018 staging (incorporates imaging and pathology, IIIC1p/IIIC2p/IIIC1r/IIIC2r annotations); Moore criteria for recurrent/metastatic prognosis (0–1 vs 2–3 vs 4–5 factors); Sedlis criteria for intermediate-risk adjuvant radiotherapy after radical hysterectomy; SHAPE trial eligibility (≤2 cm, low-risk early disease) for simple hysterectomy; EMBRACE-I protocol for MRI-guided adaptive brachytherapy planning.
→When to referRefer to gynecologic oncology at any histologic diagnosis of invasive cervical cancer; refer for fertility-sparing radical trachelectomy when stage IA1-LVSI through IB1 ≤2 cm and node-negative on sentinel mapping (2024 ESGO/ESHRE/ESGE); refer for high-volume brachytherapy center for any stage IB2–IVA disease; refer for clinical trial enrollment in recurrent/metastatic setting given rapid evolution of immunotherapy and ADC combinations.
Cervical cancer is an almost entirely HPV-driven malignancy, vaccine-preventable and screen-curable at precursor stage, yet still the fourth most common cancer in women globally because prevention and screening reach fewer than one in three women in the highest-burden regions. Stage drives management — simple hysterectomy for IA1 no-LVSI, open radical hysterectomy for IB1-IIA1, cisplatin-based chemoradiation with MR-guided adaptive brachytherapy for IB2-IVA, and pembrolizumab + platinum chemotherapy ± bevacizumab for IVB/recurrent disease — with FIGO 2018 staging, Moore criteria, and HPV ctDNA all refining risk within stage.
Cervical cancer is a largely preventable malignancy caused by persistent high-risk HPV infection, yet it remains the fourth most common cancer in women globally. This bedside reference summarizes epidemiology, risk factors, diagnosis, staging, treatment, and special populations, with emphasis on actionable thresholds and guideline-recommended therapies (NCCN v.2.2026, ESMO).

Overview and Recommendations

Background

  • •Cervical cancer is a malignant epithelial neoplasm of the uterine cervix in which persistent infection with high-risk (HPV) — types 16, 18, 31, 33, 45, 52, and 58 — drives >95% of cases, with HPV16 alone responsible for ~55–60% and HPV16/18 together ~70% of invasive disease worldwide [54, 71]. The viral oncoproteins E6 and E7 inactivate and (pRb) respectively, abolishing apoptotic and cell-cycle safeguards and permitting accumulation of cooperative host mutations — most notably PIK3CA activating mutations in ~25–30% of tumors [73, 154, 164].
  • •Cervical cancer is the fourth most common malignancy in women worldwide and the fourth leading cause of cancer-related death, with an estimated 530,000 new cases and 275,000 deaths annually, and a roughly 6-fold mortality disparity between developing and developed regions driven almost entirely by differential access to and [9, 22, 31, 37]. Median age at diagnosis is ~50 years, with most cases presenting between ages 35–55 [53, 73]. In sub-Saharan Africa it remains the leading malignancy in many countries, and women living with carry a 3–6× higher frequency of high-grade lesions, with invasive cervical cancer an AIDS-defining illness and the leading cause of cancer death among the ~20 million women with HIV worldwide [1, 38, 55, 133].
  • •The histologic landscape is dominated by (~75–80%, HPV-driven, typically immune-"hot"), followed by (~20–25%, increasingly represented in well-screened populations because cytology poorly samples the endocervical canal), and rare aggressive variants including (<2%, frequently HPV-associated, dismal prognosis) and HPV-independent gastric-type adenocarcinoma (up to 25% of adenocarcinomas in East Asia, markedly worse stage-for-stage survival) [17, 53, 54, 73, 150, 163, 174]. The 10–20 year latency from HPV infection to invasion defines the prevention window and explains why both vaccination in adolescence and screening through middle age remain essential even in vaccinated cohorts [57, 83].
  • •Cervical cancer is the paradigm of viral carcinogenesis and one of oncology's greatest success stories where prevention infrastructure exists — model-based analyses credit combined screening and CIN treatment with ~95% cervical cancer mortality reduction in long-screened populations, and a Swedish registry study of 1.67 million women followed 2006–2017 confirmed substantial invasive cancer reduction in girls vaccinated before age 17 [47, 57, 60, 62]. The WHO 90-70-90 elimination target (90% of girls vaccinated, 70% of women screened, 90% of identified disease treated) frames the global agenda [29].
  • •The 2018 revision of the system formally integrated cross-sectional and metabolic imaging and gave positive lymph nodes their own stage IIIC category — annotated IIIC1p/IIIC2p (pathologic) versus IIIC1r/IIIC2r (imaging) — replacing the older clinical-only staging that relied on the examiner's fingers and a chest x-ray [75, 168]. This stage assignment now drives every subsequent management decision: surgery versus definitive chemoradiation, fertility-sparing versus radical, and adjuvant or not [10, 168, 300].

Evaluation

  • •Suspect cervical cancer in any woman with abnormal vaginal bleeding (postcoital, intermenstrual, menorrhagic, or postmenopausal), watery or malodorous discharge, pelvic or sacral pain, dysuria/hematuria, tenesmus/hematochezia, or unexplained lower-extremity ; in resource-limited and HIV-positive populations, present at more advanced stage and with higher rates of adenocarcinoma [43, 55, 75, 168, 171].
  • •Screen asymptomatic women aged 21–29 with cytology every 3 years, and aged 30–65 with primary HPV testing every 5 years (or co-testing every 5 years, or cytology alone every 3 years) per the 2018 update; the 2018 update now permits 5-yearly primary HPV testing for women aged 30–65 [117]. Primary HPV testing largely closes the cytology sampling gap that lets adenocarcinoma persist in well-screened populations [17, 19, 53].
  • •Triage HPV-positive women with p16/Ki-67 dual-stain cytology — 5-year CIN3+ risk is 3.3% after a negative dual-stain versus 6.9% after negative cytology, with sensitivity of 94.6% for CIN2+ versus 55.4% for cytology alone in the Montreal trial [84, 116]. HPV self-sampling expands reach into under-screened populations [41, 123].
  • •Perform colposcopy with directed biopsy for any abnormal cytology or positive high-risk HPV; dilute acetic acid highlights acetowhite epithelium and targeted forceps biopsies sample the most abnormal areas, with up to four lesion-directed biopsies improving HSIL detection without losing specificity [101]. Add when the squamocolumnar junction is incompletely visualized or glandular pathology is suspected.
  • •Obtain an excisional diagnostic procedure (LEEP for suspected squamous lesions, for suspected adenocarcinoma in situ or microinvasion) when punch biopsy is inadequate — discordant cytology/histology, suspected microinvasion, or atypical glandular cells. Network meta-analysis of 19,415 women shows LEEP carries lower preterm-birth risk than CKC (RR 1.46 vs 2.27), making LEEP preferred when future fertility matters [82].
  • •Request the pathology report to specify: histologic subtype, grade, depth of stromal invasion (mm), horizontal spread, and (LVSI) — these five parameters define FIGO 2018 substages IA1/IA2 and determine whether cone biopsy is both diagnostic and therapeutic [168, 216]. Diffuse "block-positive" p16 IHC confirms transcriptionally active high-risk HPV, particularly valuable in ambiguous adenocarcinomas [216].
  • •**Stage locoregionally with ** — the preferred modality for tumor size, stromal/parametrial invasion, and lower-vaginal extension, and the only modality accurate enough to drive planning; the ACRIN 6651/GOG-183 intergroup study of 208 patients confirmed MRI significantly outperforms CT and clinical examination [229]. Diffusion-weighted MRI adds quantitative (ADC) correlation with FIGO stage [246, 254].
  • •**Stage nodally and distantly with ** — most accurate non-invasive modality for nodal staging with strong progression-free survival correlation in the 560-patient prospective cohort; pretreatment SUVmax and metabolic tumor volume predict chemoradiation outcome and reflect an inflammatory, myeloid-infiltrated microenvironment [137, 241, 258, 260]. Sensitivity in early-stage disease drops to 77% for small nodal deposits [239, 242].
  • •Consider laparoscopic para-aortic lymphadenectomy for restaging when PET shows no para-aortic uptake but pelvic nodes are positive — false-negative rates for para-aortic disease reach 12–22% in this group, and ESMO recommends laparoscopic surgical staging up to renal vessels; NCCN reserves dissection for suspicious nodes only [168, 230, 244, 247].
  • •**Perform with ultrastaging** for surgical staging of early disease (IA1-LVSI through IIA1); dual-tracer mapping (technetium-99m + patent blue) achieves ~90% bilateral detection, the SENTICOL study reported 92% sensitivity and 98.2% NPV, and a 2025 NEJM randomized trial of 838 patients confirmed non-inferiority versus complete pelvic lymphadenectomy (DFS HR 0.91, 95% CI 0.72–1.15) [58, 201, 202]. Ultrastaging at 200-μm intervals with cytokeratin AE1/AE3 detects low-volume metastases missed on H&E, and HPV DNA PCR identifies molecular-only metastases in 7% of histologically negative SLNs [97].
  • •Order baseline labs and molecular workup before treatment: CBC, comprehensive metabolic panel with renal function (eGFR for cisplatin dosing) and serum potassium, testing in all patients, pregnancy testing in those of reproductive potential, and for advanced/recurrent disease — PD-L1 combined positive score (CPS), MSI/MMR, tumor mutational burden, and for PIK3CA, HER2, and other actionable alterations [75, 154, 168, 263, 271].
  • •**Apply the ** (Black race, ECOG PS 1, pelvic-only disease, prior platinum exposure, PFS interval <365 days) to stratify prognosis in recurrent/metastatic disease — patients with 0–1, 2–3, or 4–5 factors have meaningfully divergent survival, and the score remains the reference stratification in modern trials of immune checkpoint blockade and antibody-drug conjugates [299, 306, 328, 334].

Management

  • •**Initiate ** with the 9-valent vaccine (Gardasil 9) for all children aged 9–14 in a one- or two-dose schedule per current WHO guidance; vaccination before age 17 yields the largest invasive cancer reduction (Swedish registry: 1,672,983 women followed 2006–2017) [29, 57]. Single-dose efficacy of 95.4% against persistent HPV 16/18 infection at 10-year Indian cohort follow-up supports dose-minimized schedules in resource-limited settings [83].
  • •**Perform or cone biopsy with negative margins** for stage IA1 without LVSI — these are the only patients where conservative surgery is curative and fertility-preserving [168, 295].
  • •For stage IA1 with LVSI, IA2, and IB1 ≤2 cm, the established that simple hysterectomy with nodal assessment is non-inferior to radical hysterectomy for 3-year pelvic recurrence, reshaping the standard away from routine radical surgery for low-risk early disease [10]. Radical trachelectomy remains the fertility-sparing option for women with tumors <2 cm and negative nodes on , with oncologic outcomes equivalent to radical hysterectomy per the 2024 ESGO/ESHRE/ESGE guideline [58, 136, 331, 395].
  • •Use open radical hysterectomy with pelvic lymphadenectomy for stage IB1 >2 cm and IIA1 — the ( Ramirez et al, NEJM 2018) demonstrated inferior DFS (HR 1.65) and OS at 4.5 years with minimally invasive radical hysterectomy versus open abdominal approach, making minimally invasive radical hysterectomy contraindicated outside prospective protocols [289, 300]. The SUCCOR retrospective cohort supports MIS only in selected low-risk patients with small tumors and no high-risk features [15, 59].
  • •**Administer definitive -based chemoradiotherapy** for stage IB2–IVA: external-beam radiotherapy (45–50 Gy) with concurrent weekly 40 mg/m² × 5–6 cycles plus MRI-guided adaptive brachytherapy (MR-IGABT). The 2008 individual-patient-data meta-analysis of 13 trials showed a 6% absolute 5-year survival gain (HR ~0.83, p<0.001) over radiotherapy alone (NNT ≈ 17 to prevent one death at 5 years), and EMBRACE-I (n=1,318) achieved 5-year local control >92% in stage IIB and >85% in stage IVA when MR-IGABT is incorporated [17, 99, 335].
  • •**Add concurrent ** 200 mg every 3 weeks to standard chemoradiation for locally advanced disease per NCCN update and (positive phase 3);
    • CRT in
    did not improve PFS and is not preferred [168, 297].
  • •Stratify post-hysterectomy adjuvant therapy by risk: low-risk → observation; intermediate-risk ( : ≥3 of positive LVSI, deep stromal invasion, tumor >4 cm) → adjuvant radiotherapy alone (NRG/GOG-263 showed no RFS benefit from adding weekly cisplatin in this stratum) [80, 148]; high-risk (positive nodes, margins, or parametria) → concurrent chemoradiation with cisplatin 40 mg/m² [168].
  • •For stage IVB or recurrent disease, initiate first-line ** 200 mg every 3 weeks + platinum chemotherapy ± 15 mg/kg** per — OS HR 0.63 (95% CI 0.49–0.81) in PD-L1 CPS≥1, with benefit extending to all-comers in updated analyses [52, 299, 336]. Cemiplimab (EMPOWER-Cervical 1) is an alternative second-line option enriched in CPS≥1 tumors; CPS<1 patients showed a numerical trend toward harm, informing patient selection [263].
  • •**Administer ** (tissue-factor-directed antibody-drug conjugate) for pretreated recurrent/metastatic disease after platinum failure — it targets tissue factor overexpressed in cervical SCC and is NCCN-listed for this setting.
  • •For platinum-resistant recurrence (progression <6 months from last platinum), consider second-line chemotherapy (paclitaxel, topotecan, vinorelbine) with or without bevacizumab; enroll in clinical trials of novel agents and ADC combinations whenever possible [75, 168].
  • •Manage pregnancy with stage-dependent modification: stage IA1 microinvasive disease may be observed or treated with cone biopsy in second trimester; definitive treatment before 20 weeks for invasive disease; deferring therapy until fetal pulmonary maturity (≈34–35 weeks) followed by cesarean delivery is reasonable after 20 weeks, because vaginal delivery risks hemorrhage [339, 394]. Cisplatin 40 mg/m² weekly is teratogenic in the first trimester but pooled data on platinum-taxane combinations in the second and third trimesters show acceptable fetal outcomes; breastfeeding is contraindicated during cytotoxic chemotherapy [339].
  • •For elderly patients (≥65 years), offer weekly cisplatin 40 mg/m² when organ function permits; consider carboplatin substitution for reduced creatinine clearance, ototoxicity, or comorbidity, although evidence supports preserving cisplatin dose intensity where possible [26, 75]. Initiate hormone replacement therapy in eligible survivors of ovarian failure — fewer than half of eligible survivors currently receive it [379].
  • •For HIV-positive patients, deliver standard cisplatin-based chemoradiation; in a Botswanan cohort of 348 women, HIV-positive patients on antiretroviral therapy achieved overall survival comparable to HIV-negative patients, although treatment interruptions were more frequent [55]. Coordinate with the HIV prescriber because CYP3A4-inhibiting antiretrovirals elevate taxane levels [1].
  • •Surveil with history, physical, and cytology every 3–6 months for 2 years, then every 6 months through year 5; reserve imaging for symptomatic patients or when recurrence is suspected (NCCN Category 2A), with preferred in this setting [168]. Monitor serial (ctHPV DNA) in research or high-risk settings — end-of-treatment positivity strongly predicts relapse (HR >6 for PFS in CALLA), and serial monitoring identifies molecular relapse a median of 4–6 months before clinical or radiographic progression [256, 262, 269, 273].
  • •Avoid underdosing cisplatin in women ≥65 — undertreatment of elderly patients remains a documented gap despite absolute survival benefit from concurrent chemotherapy added to radiotherapy [26]. Avoid non-protocol minimally invasive radical hysterectomy based on LACC trial inferior outcomes [300]. Avoid vaginal delivery with active invasive cervical cancer because of hemorrhage risk [394].
  • •Refer to gynecologic oncology at the time of any histologic diagnosis of invasive cervical cancer; refer for counseling when stage IA1-LVSI through IB1 ≤2 cm and node-negative, and refer for expertise for any stage IB2–IVA disease because MR-IGABT (EMBRACE-I protocol) drives 5-year local control >92% in stage IIB and is not generalizable from EBRT alone [17, 99, 331].

Board Review — High Yield

  • •HPV 16/18 — drive >70% of invasive cervical cancer; HPV16 alone accounts for ~55–60%, with E6 degrading p53 and E7 degrading pRb as the universal molecular foundation [54, 71, 164].
  • •FIGO 2018 staging — formally incorporated MRI, PET-CT, and pathology into clinical staging and created stage IIIC (IIIC1 = pelvic nodes only, IIIC2 = para-aortic nodes; p = pathologic, r = imaging) — the single decision node from which every management choice branches [75, 168].
  • •p16 IHC — diffuse "block-positive" staining is a surrogate for transcriptionally active high-risk HPV and confirms HPV-driven neoplasia, particularly in ambiguous adenocarcinomas [216].
  • •LACC trial — minimally invasive radical hysterectomy is contraindicated outside prospective protocols because of inferior DFS (HR 1.65) and OS at 4.5 years versus open abdominal radical hysterectomy [289, 300].
  • •SHAPE trial — for stage IA1-LVSI through IB1 ≤2 cm, simple hysterectomy with nodal assessment is non-inferior to radical hysterectomy for 3-year pelvic recurrence, reshaping the standard for low-risk early disease [10].
  • •EMBRACE-I — 5-year local control >92% in stage IIB and >85% in stage IVA when external-beam radiotherapy, weekly cisplatin 40 mg/m², and MRI-guided adaptive brachytherapy are combined — the modern standard for locally advanced disease [17, 99].
  • •KEYNOTE-826 — first-line pembrolizumab 200 mg q3w + platinum chemotherapy ± bevacizumab for stage IVB or recurrent disease, with OS HR 0.63 (95% CI 0.49–0.81) in PD-L1 CPS≥1 [52, 299, 336].
  • •KEYNOTE-A18 vs CALLA — concurrent pembrolizumab + CRT preferred per NCCN (KEYNOTE-A18 positive); durvalumab + CRT in CALLA did not improve PFS and is not the standard [168, 297].
  • •Moore criteria — five-factor prognostic score (Black race, ECOG PS 1, pelvic-only disease, prior platinum, PFI <365 days) validated in GOG-240 and used in modern immune checkpoint and ADC trials for recurrent/metastatic disease [299, 306, 334].
  • •ctHPV DNA — detectable post-CRT circulating tumor HPV DNA predicts relapse with HR >6 for PFS in CALLA and identifies molecular relapse 4–6 months before clinical or radiographic progression, the most validated dynamic biomarker in locally advanced disease [256, 262, 269, 273].

Deep Dive — Evidence Details

References

  1. [1]

    Reid E, Suneja G, Ambinder RF et al.. “Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30099375 ↗

    L1GUIDELINECited in: Definition and Epidemiology, Special Populations
  2. [2]

    Kalliala I, Athanasiou A, Veroniki AA et al.. “Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 31959338 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview
  3. [3]

    Bennett M, Feldmeier J, Smee R et al.. “Hyperbaric oxygenation for tumour sensitisation to radiotherapy: a systematic review of randomised controlled trials.” Cancer treatment reviews (2008). PMID: 18640781 ↗

    L1SR_MA_RCTCited in: Definition and Epidemiology
  4. [4]

    Chopra S, Gupta S, Kannan S et al.. “Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34506246 ↗

    L1RCTCited in: Definition and Epidemiology, Prognosis and Prognostic Factors
  5. [5]

    Blohmer JU, Paepke S, Sehouli J et al.. “Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21860000 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Staging
  6. [6]

    Rombouts AJM, Hugen N, van Beek JJP et al.. “Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis.” Cancer treatment reviews (2018). PMID: 29957373 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  7. [7]

    Tzioras S, Pavlidis N, Paraskevaidis E et al.. “Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis.” Cancer treatment reviews (2007). PMID: 17112673 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Management Overview
  8. [8]

    Arbyn M, Verdoodt F, Snijders PJ et al.. “Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.” The Lancet. Oncology (2014). PMID: 24433684 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis
  9. [9]

    Flint ML, Byrne ME, Friedman CF. “Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671446 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Staging, Prognosis and Prognostic Factors
  10. [10]

    Plante M, Kwon JS, Ferguson S et al.. “Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.” The New England journal of medicine (2024). PMID: 38416430 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors
  11. [11]

    Palefsky JM, Lee JY, Jay N et al.. “Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.” The New England journal of medicine (2022). PMID: 35704479 ↗

    L1RCTCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Management Overview
  12. [12]

    Tewari KS, Sill MW, Long HJ et al.. “Improved survival with bevacizumab in advanced cervical cancer.” The New England journal of medicine (2014). PMID: 24552320 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview
  13. [13]

    Naucler P, Ryd W, Törnberg S et al.. “Human papillomavirus and Papanicolaou tests to screen for cervical cancer.” The New England journal of medicine (2007). PMID: 17942872 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  14. [14]

    Sankaranarayanan R, Nene BM, Shastri SS et al.. “HPV screening for cervical cancer in rural India.” The New England journal of medicine (2009). PMID: 19339719 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  15. [15]

    Nitecki R, Ramirez PT, Frumovitz M et al.. “Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis.” JAMA oncology (2020). PMID: 32525511 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Management Overview
  16. [16]

    Cho WK, Park W, Kim SW et al.. “Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38662364 ↗

    L2RCTCited in: Definition and Epidemiology, Management Overview, Special Populations
  17. [17]

    Pötter R, Tanderup K, Schmid MP et al.. “MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.” The Lancet. Oncology (2021). PMID: 33794207 ↗

    L2TRIAL_NONRANDOMCited in: Definition and Epidemiology, Imaging, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  18. [18]

    Wentzensen N, Egemen D, Clarke MA et al.. “Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women Who Are Human Papillomavirus-Positive With Dual Stain and Human Papillomavirus Genotyping.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41701950 ↗

    L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations
  19. [19]

    Dijkstra MG, Snijders PJ, Arbyn M et al.. “Cervical cancer screening: on the way to a shift from cytology to full molecular screening.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24445150 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  20. [20]

    Zhong J, Wu L, Song Z et al.. “TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.” Cancer cell (2025). PMID: 41135519 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Management Overview, Special Populations
  21. [21]

    Schuurman TN, Schaafsma M, To KH et al.. “Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.” The Lancet. Oncology (2023). PMID: 37952541 ↗

    L3COHORTCited in: Definition and Epidemiology, Histopathology and Molecular Biology, Clinical Presentation
  22. [22]

    Monk BJ, Tewari KS, Koh WJ. “Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17617527 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Staging
  23. [23]

    Chan JK, Berek JS. “Impact of the human papilloma vaccine on cervical cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17617529 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  24. [24]

    Alimena S, Pachigolla SL, Feldman S et al.. “Race- and Age-Related Disparities in Cervical Cancer Mortality.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33789223 ↗

    L3OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
  25. [25]

    Willmott LJ, Sumner DA, Monk BJ. “Biologics in cervical cancer therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 21147904 ↗

    L5OTHERCited in: Definition and Epidemiology, Management Overview
  26. [26]

    Xiang M, Kidd EA. “Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31390586 ↗

    L2OTHERCited in: Definition and Epidemiology, Staging, Special Populations
  27. [27]

    Liu F, Wang L, Sun Q et al.. “Adverse events associated with immune checkpoint inhibitors in cervical cancer: A systematic review and meta-analysis of randomized controlled trials.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 42320227 ↗

    L1SR_MA_RCTCited in: Definition and Epidemiology
  28. [28]

    Ventriglia J, Paciolla I, Pisano C et al.. “Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.” Cancer treatment reviews (2017). PMID: 28800469 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview, Prognosis and Prognostic Factors, Special Populations
  29. [29]

    Giannone G, Giuliano AR, Bandini M et al.. “HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage.” Cancer treatment reviews (2022). PMID: 36265336 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  30. [30]

    Zagouri F, Dimitrakakis C, Marinopoulos S et al.. “Cancer in pregnancy: disentangling treatment modalities.” ESMO open (2016). PMID: 27843602 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
  31. [31]

    Bray F, Parkin DM. “Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.” The Lancet. Oncology (2022). PMID: 35550275 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Special Populations
  32. [32]

    Sauvaget C, Nishino Y, Konno R et al.. “Challenges in breast and cervical cancer control in Japan.” The Lancet. Oncology (2016). PMID: 27396648 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  33. [33]

    Iezzoni LI. “Cancer detection, diagnosis, and treatment for adults with disabilities.” The Lancet. Oncology (2022). PMID: 35358465 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Management Overview
  34. [34]

    Villarreal-Garza C, Aranda-Gutierrez A, Gonzalez-Sanchez DG et al.. “National cancer control plans in Latin America and the Caribbean: challenges and future directions.” The Lancet. Oncology (2025). PMID: 40449506 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  35. [35]

    Barbera L, Thomas G. “Venous thromboembolism in cervical cancer.” The Lancet. Oncology (2008). PMID: 18177817 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  36. [36]

    Elbanna M, Pynda Y, Kalinchuk O et al.. “Radiotherapy resources in Latin America and the Caribbean: a review of current and projected needs based on International Atomic Energy Agency data.” The Lancet. Oncology (2023). PMID: 37657478 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  37. [37]

    Thibodeau S, Yan M, Sirohi B et al.. “Impact of suboptimal cancer care in the Commonwealth: a scoping review and call to action.” The Lancet. Oncology (2025). PMID: 40449505 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  38. [38]

    Yarchoan R, Uldrick TS. “HIV-Associated Cancers and Related Diseases.” The New England journal of medicine (2018). PMID: 29539283 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  39. [39]

    Lemoupa Makajio SH, Murtas M, Kenfack B et al.. “Interventions involving community health workers and their effect on cervical cancer screening uptake in sub-Saharan Africa: a systematic review.” BMC public health (2026). PMID: 42321728 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  40. [40]

    Mi X, Lin T, Zhu X et al.. “Efficacy and safety of cadonilimab for malignant solid tumor treatment: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42292353 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors
  41. [41]

    Le Bonniec A, Woods S, McGlacken T et al.. “What are the views and experiences of human papillomavirus (HPV) self-sampling for cervical screening in high-income countries? A qualitative systematic review using the Theoretical Domains Framework.” BMC public health (2026). PMID: 42277744 ↗

    L5SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  42. [42]

    Seyyedsalehi MS, Powley WA, Boffetta P. “Talc Exposure and Risk of Ovarian Cancer: A Systematic Review and Meta-Analysis with Limited Evidence on Cervical and Endometrial Cancers.” Cancers (2026). PMID: 42192949 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  43. [43]

    Yang Y, Yu M, Zeng M. “Distant metastasis in patients with cervical cancer: A systematic review and meta-analysis of incidence rates and common sites.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42171512 ↗

    L2SR_OBSCited in: Definition and Epidemiology, Clinical Presentation
  44. [44]

    Ngoma T. “World Health Organization cancer priorities in developing countries.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16801342 ↗

    L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  45. [45]

    Arbyn M, Castellsagué X, de Sanjosé S et al.. “Worldwide burden of cervical cancer in 2008.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21471563 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  46. [46]

    La Vecchia C, Bosetti C, Lucchini F et al.. “Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19948741 ↗

    L2OTHERCited in: Definition and Epidemiology, Special Populations
  47. [47]

    Arbyn M, Raifu AO, Autier P et al.. “Burden of cervical cancer in Europe: estimates for 2004.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17369600 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations
  48. [48]

    Yang L, Fujimoto J, Qiu D et al.. “Trends in cancer mortality in Japanese adolescents and young adults aged 15-29 years, 1970-2006.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19150947 ↗

    L2OTHERCited in: Definition and Epidemiology
  49. [49]

    Pérez-Gómez B, Martínez C, Navarro C et al.. “The moderate decrease in invasive cervical cancer incidence rates in Spain (1980-2004): limited success of opportunistic screening?” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20427362 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  50. [50]

    Park JY, Kim DY, Kim JH et al.. “Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 20595451 ↗

    L2OTHERCited in: Definition and Epidemiology, Staging
  51. [51]

    Hao F, Cheng X, He J et al.. “A bibliometric analysis and visualization of trends in cervical cancer screening technologies based on dual-database analysis.” Frontiers in oncology (2026). PMID: 42294304 ↗

    L5SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  52. [52]

    Monk BJ, Colombo N, Tewari KS et al.. “First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37910822 ↗

    L1OTHERCited in: Definition and Epidemiology, Management Overview
  53. [53]

    Cohen CM, Wentzensen N, Castle PE et al.. “Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36455190 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  54. [54]

    Lei J, Arroyo-Mühr LS, Lagheden C et al.. “Human Papillomavirus Infection Determines Prognosis in Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35077203 ↗

    L2OTHERCited in: Definition and Epidemiology, Histopathology and Molecular Biology, Clinical Presentation, Prognosis and Prognostic Factors
  55. [55]

    Dryden-Peterson S, Bvochora-Nsingo M, Suneja G et al.. “HIV Infection and Survival Among Women With Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27573661 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
  56. [56]

    Castle PE, Glass AG, Rush BB et al.. “Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22851570 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  57. [57]

    Lei J, Ploner A, Elfström KM et al.. “HPV Vaccination and the Risk of Invasive Cervical Cancer.” The New England journal of medicine (2020). PMID: 32997908 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  58. [58]

    Tu H, Huang H, Li Y et al.. “Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.” The New England journal of medicine (2025). PMID: 41092328 ↗

    L1OTHERCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  59. [59]

    Melamed A, Margul DJ, Chen L et al.. “Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.” The New England journal of medicine (2018). PMID: 30379613 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors
  60. [60]

    Emmons KM, Colditz GA. “Realizing the Potential of Cancer Prevention - The Role of Implementation Science.” The New England journal of medicine (2017). PMID: 28273020 ↗

    L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  61. [61]

    Cordovil DC, da Silva Reis LD, Ferreira LSS et al.. “High-risk oncogenic HPV genotypes in vulnerable women from the Amazon: a cross-sectional retrospective study.” Virology journal (2026). PMID: 42277850 ↗

    L4COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention
  62. [62]

    Goddard KAB, Feuer EJ, Mandelblatt JS et al.. “Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.” JAMA oncology (2025). PMID: 39636625 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview, Special Populations
  63. [63]

    Cham S, Li A, Rauh-Hain JA et al.. “Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City.” JAMA oncology (2022). PMID: 34817550 ↗

    L4OTHERCited in: Definition and Epidemiology
  64. [64]

    Gopalani SV, Qin J, Baksa J et al.. “Cervical Cancer Incidence in the US-Affiliated Pacific Islands.” JAMA oncology (2024). PMID: 39264606 ↗

    L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Special Populations
  65. [65]

    Brunson A, Wun T, Abrahão R et al.. “Metastatic Recurrence Among Adolescents and Young Adults With Cancer.” JAMA oncology (2026). PMID: 41296369 ↗

    L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
  66. [66]

    Fitzmaurice C, Dicker D, Pain A et al.. “The Global Burden of Cancer 2013.” JAMA oncology (2015). PMID: 26181261 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Prognosis and Prognostic Factors, Special Populations
  67. [67]

    Ortiz AP, Ortiz-Ortiz KJ, Colón-López V et al.. “Incidence of Cervical Cancer in Puerto Rico, 2001-2017.” JAMA oncology (2021). PMID: 33443548 ↗

    L2OTHERCited in: Definition and Epidemiology
  68. [68]

    Benard VB, Castle PE, Jenison SA et al.. “Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.” JAMA oncology (2017). PMID: 27685805 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  69. [69]

    Sun M, Cole AP, Lipsitz SL et al.. “Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act: Implications for Cancer Screening.” JAMA oncology (2018). PMID: 29098266 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Staging, Prognosis and Prognostic Factors, Special Populations
  70. [70]

    . “Reducing cervical cancer mortality in India.” Cancer discovery (2013). PMID: 23847374 ↗

    L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview
  71. [71]

    Biesaga B, Mucha-Małecka A, Kruczak A et al.. “Is There Geographic Variation in Poland in the Distribution of Specific High-Risk HPV Genotypes in Normal Cervical Epithelium, Dysplastic Lesions, and Cervical Cancers?” Cancers (2026). PMID: 42279357 ↗

    L2REVIEW_NARRATIVECited in: Definition and Epidemiology
  72. [72]

    Huo M, Zhang H, Hua Y et al.. “Multiple roles of circRNAs in cervical cancer: From fundamental carcinogenic mechanisms to clinical application prospects.” Critical reviews in oncology/hematology (2026). PMID: 42259479 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  73. [73]

    Lou H, Villagran G, Boland JF et al.. “Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26080840 ↗

    L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Histopathology and Molecular Biology, Clinical Presentation, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  74. [74]

    Molinolo AA, Marsh C, El Dinali M et al.. “mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22409888 ↗

    L4OTHERCited in: Definition and Epidemiology
  75. [75]

    Koh WJ, Abu-Rustum NR, Bean S et al.. “Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659131 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  76. [76]

    Partridge EE, Abu-Rustum N, Giuliano A et al.. “Cervical cancer screening.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24616539 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Management Overview
  77. [77]

    Arbyn M, Anttila A, Jordan J et al.. “European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20176693 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Management Overview
  78. [78]

    Chang HA, Armenian SH, Dellinger TH. “Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29439180 ↗

    L5SR_OBSCited in: Risk Factors and Prevention
  79. [79]

    Li X, Rao X, Wei MJ et al.. “Extended HPV Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2/3 or Worse in a Cohort Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35948040 ↗

    L2COHORTCited in: Risk Factors and Prevention
  80. [80]

    Ryu SY, Deng W, Albuquerque K et al.. “Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40947016 ↗

    L1RCTCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  81. [81]

    Arbyn M, Simon M, de Sanjosé S et al.. “Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.” The Lancet. Oncology (2022). PMID: 35709810 ↗

    L1SR_OBSCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  82. [82]

    Athanasiou A, Veroniki AA, Efthimiou O et al.. “Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis.” The Lancet. Oncology (2022). PMID: 35835138 ↗

    L1SR_OBSCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis, Management Overview
  83. [83]

    Basu P, Malvi SG, Joshi S et al.. “Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.” The Lancet. Oncology (2021). PMID: 34634254 ↗

    L2COHORTCited in: Risk Factors and Prevention
  84. [84]

    Mayrand MH, Duarte-Franco E, Rodrigues I et al.. “Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.” The New England journal of medicine (2007). PMID: 17942871 ↗

    L1RCTCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Special Populations
  85. [85]

    Teglia F, Angelini M, Astolfi L et al.. “Global Association of COVID-19 Pandemic Measures With Cancer Screening: A Systematic Review and Meta-analysis.” JAMA oncology (2022). PMID: 35797056 ↗

    L2SR_OBSCited in: Risk Factors and Prevention
  86. [86]

    Zhang J, Zhao Y, Dai Y et al.. “Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33377903 ↗

    L1RCTCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  87. [87]

    Han K, Fyles A, Shek T et al.. “A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36037303 ↗

    L1RCTCited in: Risk Factors and Prevention, Clinical Presentation, Imaging, Management Overview
  88. [88]

    Tong H, Shen R, Wang Z et al.. “DNA ploidy cytometry testing for cervical cancer screening in China (DNACIC Trial): a prospective randomized, controlled trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19825960 ↗

    L1RCTCited in: Risk Factors and Prevention
  89. [89]

    Massad LS. “Developing guidelines for cervical cancer prevention in the face of diagnostic complexity.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24616540 ↗

    L1REVIEW_NARRATIVECited in: Risk Factors and Prevention
  90. [90]

    Abdel-Rahman O. “Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33406489 ↗

    L2OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Special Populations
  91. [91]

    Kimball KJ, Huh WK. “Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267062 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  92. [92]

    Welters MJ, Kenter GG, Piersma SJ et al.. “Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18172269 ↗

    L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention
  93. [93]

    Tewari KS. “Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31026210 ↗

    L4CASE_REPORTCited in: Risk Factors and Prevention, Clinical Presentation, Imaging, Staging
  94. [94]

    Sankaranarayanan R, Boffetta P. “Research on cancer prevention, detection and management in low- and medium-income countries.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20231304 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation
  95. [95]

    Ascunce N, Salas D, Zubizarreta R et al.. “Cancer screening in Spain.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20427360 ↗

    L2OTHERCited in: Risk Factors and Prevention, Special Populations
  96. [96]

    Hussain SK, Lenner P, Sundquist J et al.. “Influence of education level on cancer survival in Sweden.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 17785761 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  97. [97]

    Coutant C, Barranger E, Cortez A et al.. “Frequency and prognostic significance of HPV DNA in sentinel lymph nodes of patients with cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17761707 ↗

    L4OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  98. [98]

    Dieleman M, Vermeulen KM, Siebers AG et al.. “Young women with (pre)malignant cervical disease in northern Netherlands: what characterises them - A population-based cohort study.” BMC women's health (2026). PMID: 42277809 ↗

    L2COHORTCited in: Risk Factors and Prevention
  99. [99]

    Schmid MP, Lindegaard JC, Mahantshetty U et al.. “Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36599120 ↗

    L2OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Clinical Presentation, Imaging, Staging, Management Overview, Prognosis and Prognostic Factors
  100. [100]

    Star J, Bandi P, Siegel RL et al.. “Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36821800 ↗

    L2OTHERCited in: Risk Factors and Prevention
  101. [101]

    Wentzensen N, Walker JL, Gold MA et al.. “Multiple biopsies and detection of cervical cancer precursors at colposcopy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25422481 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis
  102. [102]

    Shin DW, Lee JW, Jung JH et al.. “Disparities in Cervical Cancer Screening Among Women With Disabilities: A National Database Study in South Korea.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30074846 ↗

    L2OTHERCited in: Risk Factors and Prevention
  103. [103]

    Clarke MA, Fetterman B, Cheung LC et al.. “Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29356609 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  104. [104]

    Woo PP, Kim JJ, Leung GM. “What is the most cost-effective population-based cancer screening program for Chinese women?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17308266 ↗

    L2OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  105. [105]

    Snyder CF, Earle CC, Herbert RJ et al.. “Preventive care for colorectal cancer survivors: a 5-year longitudinal study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18309941 ↗

    L2OTHERCited in: Risk Factors and Prevention
  106. [106]

    Xin R, Gong M, Guo J et al.. “Cervical cancer screening policy inequality worldwide: a systematic review of disparities in access and implementation.” Journal of translational medicine (2026). PMID: 42288897 ↗

    L2SR_OBSCited in: Risk Factors and Prevention, Clinical Presentation
  107. [107]

    Gennigens C, Jerusalem G, Lapaille L et al.. “Recurrent or primary metastatic cervical cancer: current and future treatments.” ESMO open (2022). PMID: 36108558 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
  108. [108]

    Elit L, Haruyama R, Gatti A et al.. “Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports.” ESMO open (2020). PMID: 33310778 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  109. [109]

    van Dam PA, Rolfo C, Ruiz R et al.. “Potential new biomarkers for squamous carcinoma of the uterine cervix.” ESMO open (2018). PMID: 30018810 ↗

    L5OTHERCited in: Risk Factors and Prevention
  110. [110]

    de Sanjose S, Quint WG, Alemany L et al.. “Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.” The Lancet. Oncology (2010). PMID: 20952254 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Special Populations
  111. [111]

    Sankaranarayanan R, Basu P, Kaur P et al.. “Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts.” The Lancet. Oncology (2019). PMID: 31674322 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Prognosis and Prognostic Factors
  112. [112]

    Sarfati D, Dyer R, Sam FA et al.. “Cancer control in the Pacific: big challenges facing small island states.” The Lancet. Oncology (2019). PMID: 31395476 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  113. [113]

    Westerveld H, Nesvacil N, Fokdal L et al.. “Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer.” The Lancet. Oncology (2020). PMID: 32135119 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Imaging, Prognosis and Prognostic Factors
  114. [114]

    Hadizadeh F, Koteci A, Karlsson T et al.. “Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women.” JAMA oncology (2025). PMID: 41165687 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  115. [115]

    Taksler GB, Peterse EFP, Willems I et al.. “Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.” JAMA oncology (2021). PMID: 33914025 ↗

    L2OTHERCited in: Risk Factors and Prevention
  116. [116]

    Clarke MA, Cheung LC, Castle PE et al.. “Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.” JAMA oncology (2019). PMID: 30325982 ↗

    L2OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  117. [117]

    . “Cervical Cancer Screening Every 5 Years OK.” Cancer discovery (2018). PMID: 30206109 ↗

    L5OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  118. [118]

    . “HPV Testing Bests Pap for Cervical Screening.” Cancer discovery (2018). PMID: 30054288 ↗

    L5OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  119. [119]

    Bosch FX, de Sanjose S, Castellsague X. “The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial.” Cancer discovery (2011). PMID: 22586628 ↗

    L5OTHERCited in: Risk Factors and Prevention
  120. [120]

    Xu Z, Xu J, Gu Y et al.. “Systematic review of self-management practices for vaginal irrigation among cervical cancer patients undergoing radiotherapy.” Frontiers in oncology (2026). PMID: 42318478 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  121. [121]

    Ferrall L, Lin KY, Roden RBS et al.. “Cervical Cancer Immunotherapy: Facts and Hopes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33888488 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
  122. [122]

    Tewari KS, Monk BJ. “New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25104084 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Management Overview
  123. [123]

    van den Helder R, Steenbergen RDM, van Splunter AP et al.. “HPV and DNA Methylation Testing in Urine for Cervical Intraepithelial Neoplasia and Cervical Cancer Detection.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35266975 ↗

    L2OTHERCited in: Risk Factors and Prevention
  124. [124]

    Lukovic J, Pintilie M, Han K et al.. “An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38180733 ↗

    L2OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology
  125. [125]

    Verlaat W, Snoek BC, Heideman DAM et al.. “Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29632006 ↗

    L2OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  126. [126]

    Soutter WP, Diakomanolis E, Lyons D et al.. “Dynamic spectral imaging: improving colposcopy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19223500 ↗

    L2OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  127. [127]

    Clarke MA, Gradissimo A, Schiffman M et al.. “Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29420222 ↗

    L3OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  128. [128]

    Einstein MH, Leanza S, Chiu LG et al.. “Genetic variants in TAP are associated with high-grade cervical neoplasia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19188174 ↗

    L3OTHERCited in: Risk Factors and Prevention
  129. [129]

    Ouedraogo TC, Bazie BVEJT, Simporé A et al.. “Glutathione S-Transferase Mu1 polymorphisms and environmental factors in cervical cancer susceptibility: a systematic review and meta-analysis.” Cellular and molecular biology (Noisy-le-Grand, France) (2026). PMID: 42322564 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  130. [130]

    Feng P, Shi K, Zhao W et al.. “Diagnostic value of FAM19A4/SOX1/PAX1 methylation in non-16/18 high-risk HPV cervical lesions.” Gynecologic oncology (2026). PMID: 42335608 ↗

    L2OTHERCited in: Risk Factors and Prevention
  131. [131]

    Agha S. “Impact of behavioral insights-informed social media campaigns on HPV vaccination in Bangladesh.” PLOS global public health (2026). PMID: 42335084 ↗

    L2OTHERCited in: Risk Factors and Prevention
  132. [132]

    Wagner A, Johnson EJ, Montes C et al.. “Factors Associated With Parental Willingness to Vaccinate Daughters Against Human Papillomavirus in Peru.” Health education & behavior : the official publication of the Society for Public Health Education (2026). PMID: 42333977 ↗

    L4OTHERCited in: Risk Factors and Prevention
  133. [133]

    Ma Y, Liu M. “HPV genotype distribution and risk factors for cervical dysplasia among HPV-positive women with or without HIV infection in Shanghai, China.” BMC infectious diseases (2026). PMID: 42332625 ↗

    L4OTHERCited in: Risk Factors and Prevention
  134. [134]

    Chae YK, Hong F, Vaklavas C et al.. “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32463741 ↗

    L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
  135. [135]

    Frumovitz M, Plante M, Lee PS et al.. “Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial.” The Lancet. Oncology (2018). PMID: 30143441 ↗

    L1TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
  136. [136]

    Abu-Rustum NR, Sonoda Y. “Fertility-sparing surgery in early-stage cervical cancer: indications and applications.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 21147906 ↗

    L4OTHERCited in: Histopathology and Molecular Biology, Staging, Prognosis and Prognostic Factors, Special Populations
  137. [137]

    Kidd EA, Grigsby PW. “Intratumoral metabolic heterogeneity of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698042 ↗

    L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology, Clinical Presentation, Imaging, Prognosis and Prognostic Factors, Special Populations
  138. [138]

    Colombo I, Zaccarelli E, Del Grande M et al.. “ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies.” ESMO open (2020). PMID: 32718919 ↗

    L1REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Management Overview
  139. [139]

    Siferih M, Gedif G, Lamesgen A et al.. “Point-of-care HPV testing for cervical cancer screening in Sub-Saharan Africa: platform diversity, diagnostic performance, implementation feasibility, and determinants-a scoping review with contextual considerations for Ethiopia.” BMC public health (2026). PMID: 41588417 ↗

    L5SR_OBSCited in: Histopathology and Molecular Biology
  140. [140]

    Shi F, Xuan Y, Zhu Y et al.. “Efficacy and safety of combined immune therapy for advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 42266659 ↗

    L1SR_OBSCited in: Histopathology and Molecular Biology
  141. [141]

    Böhmer G, Stolte C, Vogelmann T et al.. “Liquid-based cytology in cervical cancer screening: A systematic review and meta-analysis.” Acta cytologica (2026). PMID: 42142346 ↗

    L1SR_OBSCited in: Histopathology and Molecular Biology
  142. [142]

    Emagneneh T, Mulugeta C, Ejigu B et al.. “Burden and predictors of cervical cancer mortality in Sub-Saharan Africa: a systematic review and meta-analysis.” Infectious agents and cancer (2026). PMID: 41917998 ↗

    L1SR_OBSCited in: Histopathology and Molecular Biology
  143. [143]

    Rose PG, Java J, Whitney CW et al.. “Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732170 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  144. [144]

    Kang S, Nam BH, Park JY et al.. “Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22614984 ↗

    L3OTHERCited in: Histopathology and Molecular Biology, Imaging
  145. [145]

    Scott JG, Berglund A, Schell MJ et al.. “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.” The Lancet. Oncology (2017). PMID: 27993569 ↗

    L3OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  146. [146]

    Chu R, Wang Z, Shi S et al.. “Histology-specific prognostic models for early-stage cervical cancer based on pathologic intermediate-risk factors: a multi-center retrospective study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41576737 ↗

    L3COHORTCited in: Histopathology and Molecular Biology
  147. [147]

    Dorji N, Dorjey Y, Tshering S et al.. “Status of human papillomavirus infection after loop electrosurgical excision procedure at the National Referral Hospital, Bhutan, 2022-2023: A retrospective study.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 41521882 ↗

    L4COHORTCited in: Histopathology and Molecular Biology
  148. [148]

    Agustí N, Viveros-Carreño D, Wu CF et al.. “Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer.” JAMA oncology (2025). PMID: 40079948 ↗

    L3OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation, Management Overview, Special Populations
  149. [149]

    Ishida S, McCormick F, Smith-McCune K et al.. “Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.” Cancer cell (2010). PMID: 20541702 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Management Overview, Prognosis and Prognostic Factors, Special Populations
  150. [150]

    Zhang Y, Li C, Xiang Y. “Tumor immune microenvironment in cervical cancer: Histological subtype-specific immune landscapes and therapeutic implications.” Biochimica et biophysica acta. Reviews on cancer (2026). PMID: 41932455 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  151. [151]

    Espinosa-Riquer ZP, Muñoz-Bello JO, González-Espinosa C et al.. “Deciphering the Role of Mast Cells in HPV-Related Cancers.” International journal of molecular sciences (2025). PMID: 41465542 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  152. [152]

    Luzarraga Aznar A, Elyashiv O, Dababou S et al.. “Hormone replacement therapy in gynecologic cancer: oncologic safety and alternative therapies.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41411699 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  153. [153]

    Ouma GE, Asaso Omwodo K, Itsura P et al.. “Characterizing trimodal therapy outcomes by HIV status in early-stage cervical cancer: a retrospective cohort study from a Kenyan tertiary centre.” BMC cancer (2026). PMID: 41796282 ↗

    L3COHORTCited in: Histopathology and Molecular Biology
  154. [154]

    Friedman CF, Ravichandran V, Miller K et al.. “Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37643132 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview
  155. [155]

    Tyagi A, Vishnoi K, Mahata S et al.. “Cervical Cancer Stem Cells Selectively Overexpress HPV Oncoprotein E6 that Controls Stemness and Self-Renewal through Upregulation of HES1.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26988248 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  156. [156]

    Rockall AG, Barwick TD, Wilson W et al.. “Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34526364 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Imaging, Staging
  157. [157]

    Yuan SH, Liang XF, Jia WH et al.. “Molecular diagnosis of sentinel lymph node metastases in cervical cancer using squamous cell carcinoma antigen.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18765550 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  158. [158]

    Fjeldbo CS, Julin CH, Lando M et al.. “Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27012812 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation, Imaging
  159. [159]

    Lee CM, Fuhrman CB, Planelles V et al.. “Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16397049 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  160. [160]

    Zhu H, Gu X, Xia L et al.. “A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29549162 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Staging
  161. [161]

    Wentzensen N, Schwartz L, Zuna RE et al.. “Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22675168 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  162. [162]

    Bae SH, Park YJ, Park JB et al.. “Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17200373 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  163. [163]

    Yoshida H, Higuchi D, Takigawa W et al.. “Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges.” Journal of personalized medicine (2026). PMID: 41745365 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  164. [164]

    Gholami S, Aghbash PS, Ravanlo ZZ et al.. “Therapeutic targeting of the HPV E7 oncoprotein: Current advances and emerging strategies.” International immunopharmacology (2026). PMID: 41570748 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  165. [165]

    Bahardoust M, Ghalavand N, Shamohammadi M et al.. “Pretreatment CRP-Albumin-Lymphocyte (CALLY) Index as a Prognostic Biomarker of Survival and Recurrence-Free Survival in Patients With Early-Stage Cervical Cancer After Radical Hysterectomy: A Multicenter Retrospective Cohort Study.” Obstetrics and gynecology international (2026). PMID: 41635631 ↗

    L3COHORTCited in: Histopathology and Molecular Biology
  166. [166]

    Zhang MY, Abulajiang Y, Ji C et al.. “Epidemiology and treatment options for cervical cancer patients aged <25 Years based on SEER database and real world research.” Surgical oncology (2026). PMID: 42308701 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  167. [167]

    Teodorico E, Moro F, Criscione M et al.. “Ultrasound detection of residual cervical cancer after conization, in a retrospective monocentric analysis: the URECA study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 42235121 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  168. [168]

    Abu-Rustum NR, Campos SM, Amarnath S et al.. “Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671440 ↗

    L1GUIDELINECited in: Clinical Presentation, Imaging, Staging, Management Overview, Prognosis and Prognostic Factors
  169. [169]

    Reid E, Suneja G, Ambinder RF et al.. “AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30787130 ↗

    L1GUIDELINECited in: Clinical Presentation
  170. [170]

    Wenzel L, Osann K, Hsieh S et al.. “Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25713429 ↗

    L1RCTCited in: Clinical Presentation
  171. [171]

    Ramondetta L. “What is the appropriate approach to treating women with incurable cervical cancer?” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23486459 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  172. [172]

    Gold MA. “PET in cervical cancer--implications for 'staging,' treatment planning, assessment of prognosis, and prediction of response.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267057 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Staging
  173. [173]

    Oaknin A, Moore K, Meyer T et al.. “Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.” The Lancet. Oncology (2024). PMID: 38608691 ↗

    L1RCTCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  174. [174]

    Chu T, Meng Y, Wu P et al.. “The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry.” The Lancet. Oncology (2023). PMID: 37269846 ↗

    L2COHORTCited in: Clinical Presentation, Staging, Management Overview, Prognosis and Prognostic Factors
  175. [175]

    Monk BJ, Tewari KS, Dubot C et al.. “Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2023). PMID: 36878237 ↗

    L1RCTCited in: Clinical Presentation, Management Overview
  176. [176]

    Bright CJ, Reulen RC, Winter DL et al.. “Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study.” The Lancet. Oncology (2019). PMID: 30797674 ↗

    L2COHORTCited in: Clinical Presentation
  177. [177]

    McCredie MR, Sharples KJ, Paul C et al.. “Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.” The Lancet. Oncology (2008). PMID: 18407790 ↗

    L3COHORTCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
  178. [178]

    Nelson EL, Wenzel LB, Osann K et al.. “Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18381952 ↗

    L1RCTCited in: Clinical Presentation
  179. [179]

    Lurain K. “Treating Cancer in People With HIV.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37267514 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  180. [180]

    George GC, Andersen C, Tang X et al.. “Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adults With Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38996438 ↗

    L2OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors
  181. [181]

    Papadopoulos KP, Johnson ML, Lockhart AC et al.. “First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796520 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors, Special Populations
  182. [182]

    Ferrandina G, Ranelletti FO, Legge F et al.. “Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609015 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
  183. [183]

    Goel S, Mita AC, Mita M et al.. “A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19509177 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation
  184. [184]

    Crowley FJ, O'Cearbhaill RE, Collins DC. “Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer.” Cancer treatment reviews (2021). PMID: 34082256 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview
  185. [185]

    Mitsuhashi A, Matsui H, Usui H et al.. “Serum YKL-40 as a marker for cervical adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 18723551 ↗

    L3OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  186. [186]

    Cho Y, Kim KH, Yoon HI et al.. “Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502717 ↗

    L3OTHERCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors, Special Populations
  187. [187]

    Devi BC, Tang TS, Corbex M. “Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17434897 ↗

    L2OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Staging
  188. [188]

    Bellati F, Pernice M, Manci N et al.. “Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17307758 ↗

    L3OTHERCited in: Clinical Presentation
  189. [189]

    Hwang JH, Kim H. “Comparison of clinical outcomes between early and delayed diagnosis of cervical cancer following abnormal Pap smear results: a population-based cohort study using National Health Insurance data in South Korea.” Journal of gynecologic oncology (2026). PMID: 42210769 ↗

    L3COHORTCited in: Clinical Presentation
  190. [190]

    Jiang Q, Zhang Z, Zhou J et al.. “The role of p53-mediated signaling pathways in nicotine-induced cancer: a systematic review.” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2026). PMID: 42250592 ↗

    L5SR_OBSCited in: Clinical Presentation
  191. [191]

    D'Souza G, Gross ND, Pai SI et al.. “Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24778397 ↗

    L2OTHERCited in: Clinical Presentation
  192. [192]

    Dee EC, Laversanne M, Bhoo-Pathy N et al.. “Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis.” The Lancet. Oncology (2025). PMID: 40024257 ↗

    L2OTHERCited in: Clinical Presentation, Special Populations
  193. [193]

    Hajeer A, Salem A, Akash M et al.. “Assessing the global demand and supply of brachytherapy resources: a population-based observational study.” The Lancet. Oncology (2026). PMID: 41785895 ↗

    L2OTHERCited in: Clinical Presentation
  194. [194]

    Buhay BR, Chin JD, Han RY et al.. “Bridging the gap between infection and detection: Biological, clinical, and health system contributors to diagnostic delay in HPV-associated cervical cancer.” Critical reviews in oncology/hematology (2026). PMID: 42252068 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  195. [195]

    Kuchana SK, Repalle UK, Alahari NV et al.. “Artificial Intelligence in Oncology: A Comprehensive Cross-Cancer Translational Readiness Analysis Across 18 Malignancies.” Cancers (2026). PMID: 42192906 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  196. [196]

    Leo C, Horn LC, Rauscher C et al.. “Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17145806 ↗

    L3OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Staging
  197. [197]

    Yao H, Hao Z, Zhang X et al.. “Severe immune checkpoint inhibitor-induced 3M syndrome: a case report.” Frontiers in immunology (2026). PMID: 42292465 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Management Overview
  198. [198]

    Flannelly G, Leeson S, Jariene K et al.. “The importance of quality assurance in colposcopy in the elimination of cervical cancer: A position paper by the European Federation for Colposcopy.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 42263348 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  199. [199]

    Tulimilli SV, Karnik M, Cockroft S et al.. “Recent advancements in the application of artificial intelligence-based approaches for screening, diagnosis, prognosis and treatment of cervical cancer.” Oncology reviews (2026). PMID: 42199989 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  200. [200]

    Stanek-Widera A, Borowczak J, Skiba D et al.. “Artificial Intelligence in Cervical Cytology: Opportunities and Limitations in Screening, Triage, and Diagnostic Support.” Diagnostics (Basel, Switzerland) (2026). PMID: 42196906 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  201. [201]

    Altgassen C, Hertel H, Brandstädt A et al.. “Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18565880 ↗

    L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  202. [202]

    Lécuru F, Mathevet P, Querleu D et al.. “Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21444878 ↗

    L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Imaging
  203. [203]

    Ronco G, Giorgi-Rossi P, Carozzi F et al.. “Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.” The Lancet. Oncology (2010). PMID: 20089449 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  204. [204]

    Castle PE, Stoler MH, Wright TC et al.. “Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.” The Lancet. Oncology (2011). PMID: 21865084 ↗

    L2RCTCited in: Biopsy and Histologic Diagnosis
  205. [205]

    Rijkaart DC, Berkhof J, Rozendaal L et al.. “Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.” The Lancet. Oncology (2012). PMID: 22177579 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  206. [206]

    Leo C, Horn LC, Rauscher C et al.. “Lack of apoptotic protease activating factor-1 expression and resistance to hypoxia-induced apoptosis in cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17317823 ↗

    L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Staging
  207. [207]

    Vosooney A, Witkop CT, Cantor AG et al.. “Screening for Cervical Cancer: A Recommendation From the Women's Preventive Services Initiative.” Obstetrics and gynecology (2026). PMID: 42024880 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Special Populations
  208. [208]

    . “Screening for Cervical Cancer.” Obstetrics and gynecology (2026). PMID: 42024877 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Special Populations
  209. [209]

    Kocken M, Helmerhorst TJ, Berkhof J et al.. “Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.” The Lancet. Oncology (2011). PMID: 21530398 ↗

    L2COHORTCited in: Biopsy and Histologic Diagnosis
  210. [210]

    Lim JH, Yeap LL, Saw PS et al.. “Determinants of cervical cancer screening in Southeast Asia: A systematic review using the COM-B model and the theoretical domains framework.” Preventive medicine (2026). PMID: 41887293 ↗

    L2SR_OBSCited in: Biopsy and Histologic Diagnosis
  211. [211]

    Nakamura K, Abarzua F, Hongo A et al.. “Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 18689863 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  212. [212]

    Kim JY, Park S, Nam BH et al.. “Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19770372 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  213. [213]

    Katki HA, Kinney WK, Fetterman B et al.. “Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.” The Lancet. Oncology (2011). PMID: 21684207 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  214. [214]

    Malagón T, Kulasingam S, Mayrand MH et al.. “Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.” The Lancet. Oncology (2018). PMID: 30392810 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  215. [215]

    Huang CB, Liao GD, Zhang SK et al.. “Risk of 3-Year Cytological Progression by Baseline HPV Status Among Women With Normal Cytology: A Multicenter Cohort Study.” Cancer medicine (2026). PMID: 42011062 ↗

    L2COHORTCited in: Biopsy and Histologic Diagnosis
  216. [216]

    Alqassim E, Abu Alola MJ, Alqassim AY et al.. “Comparative Clinicopathological Features and p16 Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Cervix: A Single-Center Retrospective Cohort Study in Saudi Arabia (2020-2024).” Biomedicines (2026). PMID: 41898337 ↗

    L3COHORTCited in: Biopsy and Histologic Diagnosis, Imaging
  217. [217]

    Moore KN, Yeku OO, Howitt BE et al.. “Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.” Nature reviews. Clinical oncology (2026). PMID: 42310472 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  218. [218]

    Jindal N, Rana S, Mishra BB et al.. “Synergistic Oncogenesis Cooperative Role of Epstein Barr Virus and Human Papillomavirus in Cancer Progression.” Reviews in medical virology (2026). PMID: 42250259 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  219. [219]

    Murphy EC, Rowen TS. “Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.” Obstetrics and gynecology clinics of North America (2026). PMID: 42236073 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  220. [220]

    Ressler S, Scheiden R, Dreier K et al.. “High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 18056184 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Staging
  221. [221]

    Noordhuis MG, Eijsink JJ, Ten Hoor KA et al.. “Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19920104 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  222. [222]

    Karim R, Jordanova ES, Piersma SJ et al.. “Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19825956 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  223. [223]

    Ju XZ, Yang JM, Zhou XY et al.. “EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18223224 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  224. [224]

    Yeasmin S, Nakayama K, Ishibashi M et al.. “Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18347169 ↗

    L3OTHERCited in: Biopsy and Histologic Diagnosis
  225. [225]

    Cokan A, Al Mahdawi L, Ludovisi M et al.. “The Papanicolaou Smear Reimagined: A Narrative Review of Cervicovaginal Cytology and Molecular Biospecimens for Ovarian Cancer Detection.” Medicina (Kaunas, Lithuania) (2026). PMID: 42195126 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  226. [226]

    Latsuzbaia A, Keer SV, Broeck DV et al.. “Accuracy of Allplex HPV HR Detection Full Genotyping Assay on Cervical Samples Compared to Vaginal Self-Samples.” Journal of medical virology (2026). PMID: 42272135 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  227. [227]

    Abu-Rustum NR, Campos SM, Amarnath S et al.. “Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 41825134 ↗

    L1GUIDELINECited in: Imaging, Staging, Management Overview, Prognosis and Prognostic Factors
  228. [228]

    Koh WJ, Greer BE, Abu-Rustum NR et al.. “Cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23486458 ↗

    L1GUIDELINECited in: Imaging, Staging, Management Overview, Prognosis and Prognostic Factors
  229. [229]

    Mitchell DG, Snyder B, Coakley F et al.. “Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17179104 ↗

    L2TRIAL_NONRANDOMCited in: Imaging, Staging
  230. [230]

    Gouy S, Morice P, Narducci F et al.. “Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23857967 ↗

    L2TRIAL_NONRANDOMCited in: Imaging
  231. [231]

    Höckel M, Trott S, Dornhöfer N et al.. “Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial.” The Lancet. Oncology (2018). PMID: 29530664 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  232. [232]

    Höckel M, Wolf B, Schmidt K et al.. “Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study.” The Lancet. Oncology (2019). PMID: 31383547 ↗

    L4COHORTCited in: Imaging, Staging
  233. [233]

    Abu-Rustum NR, Yashar CM, Arend R et al.. “NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38081139 ↗

    L1OTHERCited in: Imaging, Management Overview
  234. [234]

    Koh WJ, Greer BE, Abu-Rustum NR et al.. “Cervical Cancer, Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25870376 ↗

    L1OTHERCited in: Imaging, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  235. [235]

    Rajendran JG, Greer BE. “Expanding role of positron emission tomography in cancer of the uterine cervix.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16687094 ↗

    L5REVIEW_NARRATIVECited in: Imaging, Staging, Prognosis and Prognostic Factors
  236. [236]

    Abu-Rustum NR, Yashar CM, Bean S et al.. “NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32502976 ↗

    L1OTHERCited in: Imaging
  237. [237]

    Stevanović S, Helman SR, Wunderlich JR et al.. “A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30518633 ↗

    L4TRIAL_NONRANDOMCited in: Imaging, Prognosis and Prognostic Factors
  238. [238]

    Sidonie M, Elisabete G. “Oncologic, pregnancy, and reproductive outcomes of fertility-sparing surgery in early-stage cervical cancer: a systematic review.” Surgical oncology (2026). PMID: 42114502 ↗

    L2SR_OBSCited in: Imaging, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  239. [239]

    Li T, Ma J, Pang C et al.. “Head-to-head Comparison of Fibroblast Activation Protein Inhibitors and 18F-fluorodeoxyglucose in Cervical Cancer: A Systematic Review and Meta-analysis.” Academic radiology (2026). PMID: 41881693 ↗

    L1SR_OBSCited in: Imaging
  240. [240]

    Ebrahimoghli R, Aghaei MH, Hakimi MH et al.. “Temporal trends and sources of variation in late-stage cervical cancer diagnosis in low- and middle-income countries: a systematic review and meta-analysis.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41720737 ↗

    L2SR_OBSCited in: Imaging
  241. [241]

    Kidd EA, Siegel BA, Dehdashti F et al.. “Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20308664 ↗

    L2OTHERCited in: Imaging, Staging
  242. [242]

    Chou HH, Chang TC, Yen TC et al.. “Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16382121 ↗

    L2OTHERCited in: Imaging
  243. [243]

    Mahmoud O, Einstein MH. “Which Patients With Cervical Squamous Cell Carcinoma Might Benefit From Neoadjuvant Chemotherapy?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29668367 ↗

    L5OTHERCited in: Imaging
  244. [244]

    Boughanim M, Leboulleux S, Rey A et al.. “Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18487573 ↗

    L4OTHERCited in: Imaging
  245. [245]

    Bonala SR, Raja SA, Subramanian BV et al.. “Randomized comparison of tandem-ring versus tandem-ovoid applicators in volume-based brachytherapy for cervical cancer: Dosimetric analysis and early clinical outcomes.” Brachytherapy (2026). PMID: 41679999 ↗

    L1RCTCited in: Imaging
  246. [246]

    Bollineni VR, Kramer G, Liu Y et al.. “A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumour aggressiveness in pelvic cancer.” Cancer treatment reviews (2015). PMID: 25892290 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  247. [247]

    Gouy S, Morice P, Narducci F et al.. “Nodal-staging surgery for locally advanced cervical cancer in the era of PET.” The Lancet. Oncology (2012). PMID: 22554549 ↗

    L5REVIEW_NARRATIVECited in: Imaging, Staging, Prognosis and Prognostic Factors
  248. [248]

    Duggan C, Trapani D, Ilbawi AM et al.. “National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis.” The Lancet. Oncology (2021). PMID: 34653370 ↗

    L2OTHERCited in: Imaging, Staging, Prognosis and Prognostic Factors
  249. [249]

    Höckel M, Hentschel B, Horn LC. “Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.” The Lancet. Oncology (2014). PMID: 24656439 ↗

    L4OTHERCited in: Imaging
  250. [250]

    Zhang L, Yang J, Zhang P et al.. “Association between log odds of positive lymph nodes and survival in surgically treated cervical cancer patients: a SEER database-based cohort study.” World journal of surgical oncology (2026). PMID: 41998619 ↗

    L2COHORTCited in: Imaging, Staging
  251. [251]

    Rezende B, Wolf B, Colman V et al.. “FIGO 2018 Versus Ontogenetic Staging for Locally Advanced Cervical Cancer: An International Multicenter Cohort Study Comparing the Two Classifications and Their Prognostic Implications.” Cancers (2026). PMID: 41749942 ↗

    L2COHORTCited in: Imaging
  252. [252]

    Malikova H, Graffneter K, Kremenova K et al.. “Pretreatment computed tomography L1 attenuation values: Easy reaching predicting factor for radiation-related bone insufficiency fractures in females treated for advanced cervical cancer (prospective study).” Women's health (London, England) (2026). PMID: 41746818 ↗

    L2COHORTCited in: Imaging
  253. [253]

    Pergialiotis V, Thomakos N, Lygizos V et al.. “Discrepancies Between MDT Recommendations and AI-Generated Decisions in Gynecologic Oncology: A Retrospective Comparative Cohort Study.” Cancers (2026). PMID: 41681922 ↗

    L2COHORTCited in: Imaging
  254. [254]

    Hakim PK, Zeinalkhani F, Alaeddini S et al.. “Diagnostic utility of apparent diffusion coefficient values in cervical cancer staging: A retrospective study.” European journal of radiology open (2026). PMID: 42007261 ↗

    L2COHORTCited in: Imaging
  255. [255]

    Sapkota S, Pandit S, Bhandari J et al.. “Stage Migration and Validity of the International Federation of Gynecology and Obstetrics (FIGO) 2018 Staging System for Cervical Cancer: A Retrospective Cohort Study From a Tertiary Cancer Center in Nepal.” Clinical Medicine Insights. Oncology (2026). PMID: 41884605 ↗

    L2COHORTCited in: Imaging
  256. [256]

    Seo A, Xiao W, Gjyshi O et al.. “Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680029 ↗

    L2OTHERCited in: Imaging, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  257. [257]

    Li F, Zhang Z, Cai J et al.. “Primary Preclinical and Clinical Evaluation of 68Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31843751 ↗

    L4OTHERCited in: Imaging
  258. [258]

    Floberg JM, Zhang J, Muhammad N et al.. “Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33820781 ↗

    L2OTHERCited in: Imaging, Molecular Diagnostics and Biomarkers, Special Populations
  259. [259]

    Lee J, Chang CL, Lin JB et al.. “Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29959140 ↗

    L2OTHERCited in: Imaging
  260. [260]

    Williamson CW, Zamarin D, Mayadev J. “Standardized Uptake Value Illuminates Tumor Inflammation and Treatment Response.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34016640 ↗

    L5OTHERCited in: Imaging
  261. [261]

    Baudin L, Zanella L, Lebeau A et al.. “Nonmetastatic Para-aortic Lymph Node Remodeling as a Predictor of Outcome in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41779008 ↗

    L2OTHERCited in: Imaging
  262. [262]

    Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ et al.. “Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40500687 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  263. [263]

    Tewari KS, Monk BJ, Vergote I et al.. “Survival with Cemiplimab in Recurrent Cervical Cancer.” The New England journal of medicine (2022). PMID: 35139273 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  264. [264]

    Baiden-Amissah REM, Tuyaerts S, Annibali D et al.. “Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.” Frontiers in immunology (2026). PMID: 42253973 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  265. [265]

    Parida P, Mehta A, Raj EA et al.. “Diagnostic and prognostic significance of circulating HPV cfDNA in cervical cancer: A systematic review and meta-analysis.” Critical reviews in oncology/hematology (2026). PMID: 41619873 ↗

    L1SR_OBSCited in: Molecular Diagnostics and Biomarkers
  266. [266]

    Zhao C, Li M, Chen R et al.. “Comparison of different mRNA testing technologies with HPV DNA testing for predicting ASCUS triage and post-cone excision outcomes: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 41521305 ↗

    L1SR_OBSCited in: Molecular Diagnostics and Biomarkers
  267. [267]

    Soonthornthum T, Arias-Pulido H, Joste N et al.. “Epidermal growth factor receptor as a biomarker for cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21325449 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
  268. [268]

    Li Z, Yu CP, Zhong Y et al.. “Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 21700735 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  269. [269]

    Han K, Zou J, Zhao Z et al.. “Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 37972346 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  270. [270]

    Qiao YL, Sellors JW, Eder PS et al.. “A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.” The Lancet. Oncology (2008). PMID: 18805733 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  271. [271]

    Millis SZ, Ikeda S, Reddy S et al.. “Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.” JAMA oncology (2016). PMID: 27388585 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  272. [272]

    . “Analysis identifies mutations linked to cervical cancer.” Cancer discovery (2014). PMID: 24596214 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  273. [273]

    Sivars L, Jylhä C, Crona Guterstam Y et al.. “Cell-Free Human Papillomavirus DNA Is a Sensitive Biomarker for Prognosis and for Early Detection of Relapse in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38669077 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors, Special Populations
  274. [274]

    Da Silva DM, Enserro DM, Mayadev JS et al.. “Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32816895 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  275. [275]

    Verlaat W, Snijders PJF, Novianti PW et al.. “Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28119363 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers
  276. [276]

    Wei JC, Yang J, Liu D et al.. “Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 27401250 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  277. [277]

    Brochwitz E, Nel I, Eckardt A et al.. “Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets-A New Perspective?” International journal of molecular sciences (2026). PMID: 42278404 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  278. [278]

    Xia J, Sun J, Lu D. “Early Screening for Cervical Squamous Cell Carcinoma and Precancerous Lesions Based on Surface-Enhanced Raman Spectroscopy Microarray Chips.” International journal of nanomedicine (2026). PMID: 42273176 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  279. [279]

    Mboumba Bouassa RS, Muwonga Tukisadila J, Loemba H et al.. “Human papillomavirus viral load as promising surrogate biomarker of cervical cancer risk and clinical outcome.” Expert review of molecular diagnostics (2026). PMID: 42133446 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  280. [280]

    Lian X, Qi H, Lin D et al.. “Real-world efficacy, safety, and associated biomarkers of cadonilimab in cervical cancer: a prospective observational study.” Frontiers in immunology (2026). PMID: 42125658 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  281. [281]

    Wendel SO, Brooke GM, Hu C et al.. “Targeting Cancer-Associated PCNA with AOH1996 Induces Mitotic Catastrophe and Enhances Cisplatin Therapy in Cervical Cancer.” Cancer research communications (2026). PMID: 42044624 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  282. [282]

    Mao F, Cook RJ, Lorey T et al.. “Two-phase designs for cost-effective evaluation of cancer screening tests.” Biometrics (2026). PMID: 42043340 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  283. [283]

    Li Y, Han J, Xiao S et al.. “Prognostic utility of systemic immune-inflammation markers in locally advanced cervical cancer undergoing radical radiotherapy.” The oncologist (2026). PMID: 42015386 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers
  284. [284]

    Rothnie K, Tristano E, Diaz-Rodriguez M et al.. “Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer.” Gynecologic oncology (2026). PMID: 42000375 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  285. [285]

    Novak EN, Ma A, Hansen CJ et al.. “Mock Samples That Mimic Human Cervicovaginal Samples to Accelerate the Development and Evaluation of Assays for High-Risk HPV for Cervical Cancer Screening.” Journal of medical virology (2026). PMID: 41989210 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  286. [286]

    Sugiyama T, Fujiwara K, Ohashi Y et al.. “Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24569914 ↗

    L1RCTCited in: Staging, Prognosis and Prognostic Factors, Special Populations
  287. [287]

    Cetina L, González-Enciso A, Cantú D et al.. “Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23609186 ↗

    L1RCTCited in: Staging
  288. [288]

    Kenter GG, Greggi S, Vergote I et al.. “Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37656948 ↗

    L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  289. [289]

    Ramirez PT, Robledo KP, Frumovitz M et al.. “LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38810208 ↗

    L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  290. [290]

    Gupta S, Maheshwari A, Parab P et al.. “Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29432076 ↗

    L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  291. [291]

    Ferguson SE, Brotto LA, Kwon J et al.. “Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 39353164 ↗

    L1RCTCited in: Staging, Prognosis and Prognostic Factors
  292. [292]

    Zuliani AC, Esteves SC, Teixeira LC et al.. “Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24449243 ↗

    L1RCTCited in: Staging
  293. [293]

    Katsumata N, Hirai Y, Kamiura S et al.. “Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21345941 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  294. [294]

    Marchetti C, Fagotti A, Tombolini V et al.. “Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 31838220 ↗

    L1SR_OBSCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  295. [295]

    Gray HJ. “Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267058 ↗

    L5REVIEW_NARRATIVECited in: Staging, Management Overview, Prognosis and Prognostic Factors
  296. [296]

    Pennington KP, Urban RR, Gray HJ. “Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659132 ↗

    L5REVIEW_NARRATIVECited in: Staging, Prognosis and Prognostic Factors
  297. [297]

    Monk BJ, Toita T, Wu X et al.. “Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 38039991 ↗

    L1RCTCited in: Staging, Management Overview
  298. [298]

    Mileshkin LR, Moore KN, Barnes EH et al.. “Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37080223 ↗

    L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  299. [299]

    Colombo N, Dubot C, Lorusso D et al.. “Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.” The New England journal of medicine (2021). PMID: 34534429 ↗

    L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  300. [300]

    Ramirez PT, Frumovitz M, Pareja R et al.. “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.” The New England journal of medicine (2018). PMID: 30380365 ↗

    L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  301. [301]

    Nam JH, Park JY, Kim DY et al.. “Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 21841155 ↗

    L2COHORTCited in: Staging, Prognosis and Prognostic Factors
  302. [302]

    Huang H, Feng YL, Wan T et al.. “Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33443541 ↗

    L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  303. [303]

    Frumovitz M, Obermair A, Coleman RL et al.. “Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.” The Lancet. Oncology (2020). PMID: 32502445 ↗

    L1TRIAL_NONRANDOMCited in: Staging, Special Populations
  304. [304]

    Youn JW, Hur SY, Woo JW et al.. “Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.” The Lancet. Oncology (2020). PMID: 33271094 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  305. [305]

    Penson RT, Huang HQ, Wenzel LB et al.. “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).” The Lancet. Oncology (2015). PMID: 25638326 ↗

    L1TRIAL_NONRANDOMCited in: Staging
  306. [306]

    Tewari KS, Sill MW, Monk BJ et al.. “Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26672085 ↗

    L1RCTCited in: Staging, Prognosis and Prognostic Factors
  307. [307]

    de la Rochefordiere A, Kamal M, Floquet A et al.. “PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25724520 ↗

    L2RCTCited in: Staging
  308. [308]

    Uppal S, Gehrig PA, Peng K et al.. “Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32031867 ↗

    L2REVIEW_NARRATIVECited in: Staging
  309. [309]

    Strauss J, Heery CR, Schlom J et al.. “Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29298798 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  310. [310]

    Attademo L, Tuninetti V, Pisano C et al.. “Immunotherapy in cervix cancer.” Cancer treatment reviews (2020). PMID: 32827839 ↗

    L5REVIEW_NARRATIVECited in: Staging, Management Overview, Prognosis and Prognostic Factors
  311. [311]

    Pectasides D, Kamposioras K, Papaxoinis G et al.. “Chemotherapy for recurrent cervical cancer.” Cancer treatment reviews (2008). PMID: 18657909 ↗

    L5REVIEW_NARRATIVECited in: Staging, Management Overview, Prognosis and Prognostic Factors
  312. [312]

    Saini SK, Srivastava S, Goel A et al.. “Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis.” International journal of radiation oncology, biology, physics (2026). PMID: 42034194 ↗

    L1SR_OBSCited in: Staging
  313. [313]

    Kodama J, Hasengaowa, Kusumoto T et al.. “Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17032700 ↗

    L4OTHERCited in: Staging
  314. [314]

    Wang Y, Yue ZN, Yang H. “Impact of adjuvant therapy after radical hysterectomy for early-stage cervical cancer on mortality and recurrence: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 42137156 ↗

    L1SR_OBSCited in: Staging
  315. [315]

    Tjokroprawiro BA, Sulistya HA, Wijaya N et al.. “Clinicopathological characteristics and outcomes of gastric-type adenocarcinoma of the cervix: a systematic review.” AJOG global reports (2026). PMID: 42005548 ↗

    L4SR_OBSCited in: Staging
  316. [316]

    Ryzhov A, Corbex M, Piñeros M et al.. “Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study.” The Lancet. Oncology (2021). PMID: 33556324 ↗

    L2OTHERCited in: Staging, Prognosis and Prognostic Factors
  317. [317]

    Wei W, Ku D, Rutherford N. “Prognostic Value of Combined FDG PET and MRI Analysis of Cervical Cancer: A Systematic Review and Meta-Analysis.” Journal of medical radiation sciences (2026). PMID: 42316916 ↗

    L2SR_OBSCited in: Staging
  318. [318]

    Ayeni OA, Mmereki D, Mistry H et al.. “Disease characteristics, treatment, and overall survival outcomes of patients with locally advanced cervical cancer referred for radiation therapy in Johannesburg, South Africa: a 2-year retrospective study.” BMC women's health (2026). PMID: 42310589 ↗

    L2COHORTCited in: Staging
  319. [319]

    Wei Y, Song F, Wang W. “Expression levels of serum SCC, HE4, and TSGF in cervical cancer patients and their correlation with recurrence: a retrospective study.” Frontiers in medicine (2026). PMID: 42200085 ↗

    L3COHORTCited in: Staging
  320. [320]

    Kim JH, Hwang WY, Choi CH et al.. “Oncologic outcomes and the impact of minimally invasive surgery in early-stage cervical cancer patients undergoing radical trachelectomy: A retrospective multicenter cohort study from the Korean Gynecologic Oncology Group Study (KGOG 1048).” Gynecologic oncology (2026). PMID: 42013607 ↗

    L2COHORTCited in: Staging, Prognosis and Prognostic Factors, Special Populations
  321. [321]

    Du Q, Liu Q, Zhou Y et al.. “Primary prophylaxis with pegylated G-CSF is associated with improved treatment completion and progression-free survival in locally advanced cervical cancer undergoing concurrent chemoradiotherapy: a retrospective cohort study.” Future oncology (London, England) (2026). PMID: 41930746 ↗

    L2COHORTCited in: Staging, Prognosis and Prognostic Factors
  322. [322]

    Nguyen AT, Luu M, Mallen-St Clair J et al.. “Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma.” JAMA oncology (2020). PMID: 32816023 ↗

    L2OTHERCited in: Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  323. [323]

    . “Simple Hysterectomy Safe for Some Cervical Cancers.” Cancer discovery (2023). PMID: 37276328 ↗

    L5OTHERCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  324. [324]

    Hamada K, Umemiya M, Yamanoi K et al.. “Nationwide trends in surgery selection and minimally invasive surgery for cervical cancer with preoperative T1B1/T1B2 disease in Japan.” International journal of clinical oncology (2026). PMID: 42286379 ↗

    L2REVIEW_NARRATIVECited in: Staging
  325. [325]

    Meynard C, Fardeau E, Lambert T et al.. “Immunotherapy in Locally Advanced Cervical Carcinoma: A Narrative Review.” Cancers (2026). PMID: 42122204 ↗

    L5REVIEW_NARRATIVECited in: Staging
  326. [326]

    Kang Z, Stevanović S, Hinrichs CS et al.. “Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28899967 ↗

    L4OTHERCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  327. [327]

    Chaudary N, Pintilie M, Jelveh S et al.. “Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 27697997 ↗

    L5OTHERCited in: Staging, Prognosis and Prognostic Factors
  328. [328]

    Lorusso D, Colombo N, Dubot C et al.. “Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39393777 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  329. [329]

    Kitagawa R, Katsumata N, Shibata T et al.. “Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732161 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  330. [330]

    Xia L, Zhang K, Tang Y et al.. “Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40561369 ↗

    L1RCTCited in: Management Overview, Special Populations
  331. [331]

    Morice P, Scambia G, Abu-Rustum NR et al.. “Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE.” The Lancet. Oncology (2024). PMID: 39216500 ↗

    L1GUIDELINECited in: Management Overview, Special Populations
  332. [332]

    Ryu SY, Nam BH, Kim MH et al.. “A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.” ESMO open (2026). PMID: 41812622 ↗

    L1RCTCited in: Management Overview, Special Populations
  333. [333]

    Yang X, Ren H, Li Z et al.. “A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer.” ESMO open (2022). PMID: 35994789 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors
  334. [334]

    Vergote I, González-Martín A, Fujiwara K et al.. “Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.” The New England journal of medicine (2024). PMID: 38959480 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  335. [335]

    . “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19001332 ↗

    L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
  336. [336]

    Tewari KS, Colombo N, Monk BJ et al.. “Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.” JAMA oncology (2024). PMID: 38095881 ↗

    L1RCTCited in: Management Overview
  337. [337]

    Birrer M, Li G, Yunokawa M et al.. “Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 39052242 ↗

    L4RCTCited in: Management Overview, Special Populations
  338. [338]

    Zhang J, Liu R, Wang S et al.. “Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40288679 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  339. [339]

    Zagouri F, Korakiti AM, Zakopoulou R et al.. “Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis.” Cancer treatment reviews (2019). PMID: 31442939 ↗

    L4SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  340. [340]

    Andrade MO, Al-Alam OCM, Kim HJS et al.. “Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2025). PMID: 40408847 ↗

    L1SR_OBSCited in: Management Overview
  341. [341]

    Petrelli F, Riboldi V, Bruschieri L et al.. “First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis.” Cancer treatment reviews (2025). PMID: 40086103 ↗

    L1SR_OBSCited in: Management Overview
  342. [342]

    Chung HC, Ros W, Delord JP et al.. “Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30943124 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  343. [343]

    Frenel JS, Le Tourneau C, O'Neil B et al.. “Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29095678 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors
  344. [344]

    Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE et al.. “Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37651655 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  345. [345]

    Xu Q, Wang J, Sun Y et al.. “Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35192397 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  346. [346]

    Tabernero J, Andre F, Blay JY et al.. “Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.” ESMO open (2022). PMID: 35305400 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  347. [347]

    Coleman RL, Lorusso D, Gennigens C et al.. “Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.” The Lancet. Oncology (2021). PMID: 33845034 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  348. [348]

    Gao X, Xu N, Li Z et al.. “Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.” The Lancet. Oncology (2023). PMID: 37797632 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  349. [349]

    Li K, Chen J, Hu Y et al.. “Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 38048802 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  350. [350]

    Mayadev JS, Enserro D, Lin YG et al.. “Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.” JAMA oncology (2020). PMID: 31774464 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  351. [351]

    Lan C, Zhang P, Zhao J et al.. “Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer.” Cancer discovery (2026). PMID: 41511850 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  352. [352]

    Xu Q, Deng Z, Liu J et al.. “Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.” Cancer discovery (2026). PMID: 41297028 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  353. [353]

    Kyrgiou M, Mitra A, Paraskevaidis E. “Fertility and Early Pregnancy Outcomes Following Conservative Treatment for Cervical Intraepithelial Neoplasia and Early Cervical Cancer.” JAMA oncology (2016). PMID: 27356074 ↗

    L2SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  354. [354]

    Moore DH. “Chemotherapy for advanced, recurrent, and metastatic cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267059 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  355. [355]

    Dyer BA, Zamarin D, Eskandar RN et al.. “Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659133 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  356. [356]

    Hong DS, Concin N, Vergote I et al.. “Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796521 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  357. [357]

    Lou H, Cai H, Huang X et al.. “Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38372727 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  358. [358]

    Oaknin A, Ghamande SA, Kasamatsu Y et al.. “Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38165683 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview
  359. [359]

    Boding SA, Webb SN, Butler T et al.. “Experiences of Inclusion and Exclusion Across the Gynaecological Cancer Continuum for Individuals With Diverse Gender and Sexuality Backgrounds: A Systematic Review.” Psycho-oncology (2026). PMID: 42261114 ↗

    L2SR_OBSCited in: Management Overview
  360. [360]

    Zhang D, Meng Y, Dong X et al.. “Efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42253994 ↗

    L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
  361. [361]

    Verleye L, Vergote I, Reed N et al.. “Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer--Gynecological Cancer Group (EORTC-GCG).” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19556323 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  362. [362]

    Park JY, Kim DY, Kim JH et al.. “Management of occult invasive cervical cancer found after simple hysterectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19858083 ↗

    L3OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  363. [363]

    Krahl P, Kuroda K, Contreras J et al.. “The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2026). PMID: 42334174 ↗

    L1SR_OBSCited in: Management Overview
  364. [364]

    Garcia J, Hurwitz HI, Sandler AB et al.. “Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.” Cancer treatment reviews (2020). PMID: 32335505 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  365. [365]

    Wenzel HHB, Olthof EP, Bekkers RLM et al.. “Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.” Cancer treatment reviews (2022). PMID: 34773774 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  366. [366]

    Monk BJ, Enomoto T, Kast WM et al.. “Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.” Cancer treatment reviews (2022). PMID: 35413489 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  367. [367]

    Tolcher A, Hamilton E, Coleman RL. “The evolving landscape of antibody-drug conjugates in gynecologic cancers.” Cancer treatment reviews (2023). PMID: 37023499 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  368. [368]

    Wieringa HW, van der Zee AG, de Vries EG et al.. “Breaking the DNA damage response to improve cervical cancer treatment.” Cancer treatment reviews (2016). PMID: 26643553 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  369. [369]

    Diaz-Padilla I, Duran I, Clarke BA et al.. “Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.” Cancer treatment reviews (2012). PMID: 22381585 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  370. [370]

    Cabel L, Bonneau C, Bernard-Tessier A et al.. “HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.” ESMO open (2021). PMID: 34022731 ↗

    L2OTHERCited in: Management Overview
  371. [371]

    Querleu D, Morrow CP. “Classification of radical hysterectomy.” The Lancet. Oncology (2008). PMID: 18308255 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  372. [372]

    Rob L, Halaska M, Robova H. “Nerve-sparing and individually tailored surgery for cervical cancer.” The Lancet. Oncology (2010). PMID: 20202614 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  373. [373]

    Lheureux S, Butler MO, Clarke B et al.. “Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.” JAMA oncology (2018). PMID: 29145543 ↗

    L4OTHERCited in: Management Overview, Special Populations
  374. [374]

    Wang Y, Farmer M, Izaguirre EW et al.. “Association of Definitive Pelvic Radiation Therapy With Survival Among Patients With Newly Diagnosed Metastatic Cervical Cancer.” JAMA oncology (2018). PMID: 30054609 ↗

    L2OTHERCited in: Management Overview
  375. [375]

    Lecointre M, Guillot J, Marcone R et al.. “HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine.” Cancer discovery (2025). PMID: 40287949 ↗

    L5OTHERCited in: Management Overview
  376. [376]

    . “Cervical Cancer Analysis Reveals New Mutations.” Cancer discovery (2017). PMID: 28179363 ↗

    L5OTHERCited in: Management Overview
  377. [377]

    Colbert LE, El Alam MB, Wang R et al.. “Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring.” Cancer cell (2023). PMID: 37863066 ↗

    L5OTHERCited in: Management Overview
  378. [378]

    . “Strong HPV Vaccine Response Predicts Better Survival with Chemotherapy.” Cancer discovery (2020). PMID: 32220926 ↗

    L5OTHERCited in: Management Overview
  379. [379]

    Osawa N, Chikazawa K, Ko H et al.. “Follow-up by resident physicians is associated with underuse of hormone replacement therapy after cervical cancer treatment: A retrospective study.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 42107240 ↗

    L3COHORTCited in: Management Overview, Special Populations
  380. [380]

    Bonfill-Teixidor E, Neva-Alejo A, Arias A et al.. “Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39078728 ↗

    L5OTHERCited in: Management Overview
  381. [381]

    Lyng H, Skipar K, Hompland T. “Targeted Therapy on the Screen: Do We Hit the Target?” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36240006 ↗

    L5OTHERCited in: Management Overview
  382. [382]

    Miller KM, Friedman CF. “Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35947045 ↗

    L5OTHERCited in: Management Overview
  383. [383]

    Mondini M, Deutsch E. “(Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33986023 ↗

    L5OTHERCited in: Management Overview
  384. [384]

    Sannigrahi MK, Sharma R, Singh V et al.. “Role of Host miRNA Hsa-miR-139-3p in HPV-16-Induced Carcinomas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28143871 ↗

    L5OTHERCited in: Management Overview, Special Populations
  385. [385]

    Lin Z, Bazzaro M, Wang MC et al.. “Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19147762 ↗

    L5OTHERCited in: Management Overview
  386. [386]

    Cantidio FS, Costa Diniz PH, Gil G et al.. “Bone marrow-sparing radiotherapy in women with cervical cancer treated with radiochemotherapy.” The Cochrane database of systematic reviews (2026). PMID: 42273975 ↗

    L5SR_OBSCited in: Management Overview
  387. [387]

    Lin J, He H, Liu B et al.. “The exploration of iparomlimab and tuvonralimab combined with de-escalated chemotherapy as an innovative neoadjuvant treatment strategy for locally advanced cervical cancer: a case report from the NICE-CC trial.” Frontiers in immunology (2026). PMID: 42112362 ↗

    L4CASE_REPORTCited in: Management Overview
  388. [388]

    Stalp JL, Schneider JA, Steinkasserer L et al.. “Comparing clinical decision-making between colposcopists and large language models in cervical dysplasia management: a pilot prospective multicenter study.” Archives of gynecology and obstetrics (2026). PMID: 42313159 ↗

    L2OTHERCited in: Management Overview
  389. [389]

    Gosecka M, Gosecki M, Urbaniak M et al.. “Unimolecular micelles as an effective carrier of poorly water-soluble nifuratel for selective in vivo anticervical cancer therapy via mucoadhesive dynamic hydrogels.” Journal of materials chemistry. B (2026). PMID: 42300096 ↗

    L5OTHERCited in: Management Overview
  390. [390]

    Ferede YA, Zeleke AM, Tassew WC et al.. “Cervical Cancer Screening Utilization and Its Associated Factors Among Women Living With HIV in Public Health Facilities of Gondar Town, Northwest Ethiopia.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 42299655 ↗

    L2OTHERCited in: Management Overview
  391. [391]

    Li Y, Zhang J, Wu S et al.. “The impact of gut microbiota on cervical cancer and precancerous lesions: neglected status, mechanisms, challenges, and a call to action.” Frontiers in immunology (2026). PMID: 42292452 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  392. [392]

    Kankaria A, Shukla P, Vijayakumar M et al.. “Enhancing screening, early diagnosis and treatment initiation of oral, breast and cervical cancer in selected districts of India: an implementation research protocol.” BMJ open (2026). PMID: 42285578 ↗

    L5OTHERCited in: Management Overview
  393. [393]

    . “Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.” The New England journal of medicine (2007). PMID: 17494925 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  394. [394]

    Azim HA, Peccatori FA, Pavlidis N. “Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors.” Cancer treatment reviews (2010). PMID: 20015593 ↗

    L5SR_OBSCited in: Prognosis and Prognostic Factors, Special Populations
  395. [395]

    Bentivegna E, Gouy S, Maulard A et al.. “Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.” The Lancet. Oncology (2016). PMID: 27299280 ↗

    L2SR_OBSCited in: Prognosis and Prognostic Factors, Special Populations
  396. [396]

    O'Malley DM, Neffa M, Monk BJ et al.. “Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34932394 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
  397. [397]

    Naumann RW, Hollebecque A, Meyer T et al.. “Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31487218 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
  398. [398]

    Habbous S, Pang V, Eng L et al.. “p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23065429 ↗

    L1SR_OBSCited in: Prognosis and Prognostic Factors
  399. [399]

    Jabłońska IA, Goławski M, Ścieglińska D et al.. “Prognostic Value of Pretreatment Circulating Tumor HPV DNA Load in HPV-Associated Cancers: A Systematic Review and Meta-Analysis.” International journal of molecular sciences (2026). PMID: 42196246 ↗

    L1SR_OBSCited in: Prognosis and Prognostic Factors
  400. [400]

    Wang X, Zhang Y, Wang C et al.. “Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.” Frontiers in immunology (2026). PMID: 42079658 ↗

    L1SR_OBSCited in: Prognosis and Prognostic Factors
  401. [401]

    Panczel I, Herold M, Borbenyi E et al.. “Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities: Results of a Pilot Study and Meta-Analysis.” Medical sciences (Basel, Switzerland) (2026). PMID: 41892820 ↗

    L2SR_OBSCited in: Prognosis and Prognostic Factors
  402. [402]

    Zhou L, Sun C, Diao P et al.. “Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis.” Frontiers in immunology (2026). PMID: 41869324 ↗

    L1SR_OBSCited in: Prognosis and Prognostic Factors
  403. [403]

    Zhou J, Ye W, Ranarisoa SN et al.. “Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis.” Frontiers in immunology (2026). PMID: 41822503 ↗

    L1SR_OBSCited in: Prognosis and Prognostic Factors
  404. [404]

    Shibata K, Kajiyama H, Ino K et al.. “Twist expression in patients with cervical cancer is associated with poor disease outcome.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 17925286 ↗

    L4OTHERCited in: Prognosis and Prognostic Factors
  405. [405]

    He C, Li F, He M et al.. “The false-negative rate of sentinel lymph node biopsy and its related factors in early-stage cervical cancer: a systematic review and meta-analysis.” Acta oncologica (Stockholm, Sweden) (2026). PMID: 41837848 ↗

    L2SR_OBSCited in: Prognosis and Prognostic Factors
  406. [406]

    Rob L, Skapa P, Robova H. “Fertility-sparing surgery in patients with cervical cancer.” The Lancet. Oncology (2011). PMID: 20619737 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors, Special Populations
  407. [407]

    Berger AC, Korkut A, Kanchi RS et al.. “A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.” Cancer cell (2018). PMID: 29622464 ↗

    L2OTHERCited in: Prognosis and Prognostic Factors
  408. [408]

    Chen J, Chen C, Zhan Y et al.. “Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33766815 ↗

    L4OTHERCited in: Prognosis and Prognostic Factors
  409. [409]

    Kim SS, Shen S, Miyauchi S et al.. “B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32193227 ↗

    L2OTHERCited in: Prognosis and Prognostic Factors
  410. [410]

    Lan C, Shen J, Wang Y et al.. “Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 33052760 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  411. [411]

    Kyrgiou M, Athanasiou A, Arbyn M et al.. “Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP.” The Lancet. Oncology (2022). PMID: 35901834 ↗

    L1REVIEW_NARRATIVECited in: Special Populations
  412. [412]

    Healey J, Singh M, Richards C et al.. “The association of pregnancy complications/risk factors with the development of cancer in women: an umbrella review.” BMC medicine (2026). PMID: 41975433 ↗

    L1SR_OBSCited in: Special Populations
  413. [413]

    Arakawa A, Ichikawa H, Kubo T et al.. “Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.” The New England journal of medicine (2021). PMID: 33406329 ↗

    L4CASE_REPORTCited in: Special Populations
  414. [414]

    Ogasawara A, Suzuki S, Oda K et al.. “Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).” Gynecologic oncology (2026). PMID: 42013608 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  415. [415]

    Van Nieuwenhuysen E, Vergote I, Randall LM et al.. “Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.” Gynecologic oncology (2026). PMID: 42000372 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations
  416. [416]

    Rodriguez D, Fonseca T, King TS et al.. “Cervical Cancer Screening Patterns and Outcomes in Women Over 65 Years Old: A Retrospective Study of Medicare Patients.” Journal of lower genital tract disease (2026). PMID: 42024538 ↗

    L3COHORTCited in: Special Populations
  417. [417]

    Chen X, Han S, Wang S et al.. “Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19118071 ↗

    L3OTHERCited in: Special Populations
  418. [418]

    Lee JW, Choi CH, Choi JJ et al.. “Altered MicroRNA expression in cervical carcinomas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18451214 ↗

    L3OTHERCited in: Special Populations

Revision History

All updates applied to this page

Loading revisions…